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ABSTRACT 
 
Alzheimer’s disease (AD) is a complex and heterogeneous age-related disorder, and the most common 
form of dementia. Typical abnormalities in brain include neurodegeneration, gliosis, chronic 
inflammation, excitotoxicity, oxidative stress, as well as accumulation and abnormal post-translational 
modification of proteins. Despite extensive research for decades, the exact primary and secondary 
pathogenetic causes of the disorder still remain largely unknown. As a consequence of rapid 
demographic aging, AD has become one of the most devastating socioeconomical challenges of the 
present-day. Now, the new hope of unraveling the secrets of AD is the so-called “New technologies” 
i.e. proteomics, which have been suggested to represent a breakthrough in improving our 
understanding, diagnosis, and treatment of AD. The present studies were undertaken in order to 
develop methodologies in proteomic analysis of differentially post-translationally modified proteins, 
and to compare brain and cerebrospinal fluid proteomes in AD patients as compared to age-matched 
controls. In addition, the aim was to examine whether changes in post-translationally modified proteins 
were linked to the stage of AD as well as to the extent of brain pathology.  
Proteomic analysis aims at simultaneous separation, quantification and identification of protein 
isoforms over the largest possible scale. We performed proteomic analysis using two-dimensional gel 
electrophoresis in combination with immunoblotting and mass spectrometry. In addition to the 
quantification, modifications, which may crucially influence the functional output of a protein in a cell, 
are accessible to study by slightly modifying proteome analysis techniques. We examined oxidatively 
modified carbonylated proteins in brain and cerebrospinal fluid of AD patients by two-dimensional 
multiplexed oxyblotting, a method which was developed during this thesis work. Glycosylation and 
phosphorylation of glial fibrillary acidic protein were studied by removing these modifications 
enzymatically prior to two-dimensional immunoblotting. When compared to native two-dimensional 
images, any disappearing groups are indicative of the presence of the modification in question. 
We detected about 150 proteins and more than 100 oxidised proteins in both AD and control brains. 
Cytosolic malate dehydrogenase and glutamate dehydrogenase were characterized as being less 
oxidised proteins in AD brain as compared to age-matched controls. Moreover, the changes were 
associated with the duration of AD but not with brain pathology. These findings may be interpreted as 
compensatory changes occurring in response to compromised metabolism in AD. 
Twentytwo oxidatively modified proteins were characterised in cerebrospinal fluid of AD patients and 
controls. The levels of identified cerebrospinal fluid proteins were generally decreased whereas the 
degree of oxidation tended to remain either unchanged or increased in AD as compared to controls. 
None of the brain-specific proteins exhibited significant changes in the extent of oxidative 
modification in AD.  
About 46 isoforms and degradation products were separated and quantified by two-dimensional 
immunoblotting. The statistical analysis revealed a 60% increase in the amount of more acidic 
isoforms of glial fibrillary acidic protein in AD when compared to controls. These isoforms were both 
phosphorylated and N-glycosylated whereas O-glycosylated basic isoforms revealed no quantitative 
differences between the groups. The data suggest that glial fibrillary acidic protein may be another 
abnormally phosphorylated and glycosylated protein related to the pathogenesis of AD.  
To conclude, the results emphasize the importance of studying the modifications occurring to proteins 
in neurodegenerative disorders. By better understanding modifications of proteins in AD patients, 
new aspects of the pathogenesis and therapeutic targets may be discovered. 
 
National Library of Medicine Classification: WT 155, QU 58.5, QU 475, WL 203 
Medical Subject Headings: Alzheimer Disease; Alzheimer Disease/etiology; Proteins; Protein 
Processing, Post-Translational; Proteomics; Brain; Cerebrospinal Fluid; Electrophoresis, Gel, Two-
Dimensional; Immunoblotting; Spectrum Analysis, Mass 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Believe those who are seeking the truth; doubt those who find it. 
-André Gide- 
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1. INTRODUCTION 
 
The population is aging, particularly in the Western world, and society is confronted by new 
challenges in understanding, diagnosing, and treating complex and heterogeneous age-related 
disorders such as dementia. The most common cause of dementia is Alzheimer’s disease (AD) 
that is characterised by a progressive decline in memory and cognitive functions. The classical 
neuropathological hallmarks of AD brains are extracellular deposits of amyloid-beta (Aβ) 
containing plaques and intracellular neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau protein. However, these changes are not specific for AD and have 
also been reported in brains from cognitively unimpaired elderly individuals (Gold et al. 2000, 
Davies 2001, Riley et al. 2002). Other essential pathological abnormalities are neuronal death, 
gliosis, chronic inflammation, excitotoxicity and oxidative stress (Pereira et al. 2005). All 
known pathological alterations in AD complement each other and are undoubtedly involved in 
the vicious circle of the pathogenesis. Nonetheless, their role in explaining the diverse clinical 
symptoms and progression of AD is still largely unclear.  
 
AD is a pathologically complex and aetiologically multifactorial disease. There are three 
causative genes which have been linked to the small proportion of patients with early-onset 
familiar AD. In addition, a number of other candidate genetic risk factors predisposing for AD 
have been identified (Rocchi et al. 2003). However, it has become evident that genes alone 
cannot explain the late-onset sporadic AD. In addition, many environmental factors contribute 
significantly to the development of the disease. The word proteome means the entire protein 
complement expressed by a genome, or by a cell or a tissue type at any given time (Wilkins et 
al. 1996). Unlike the genome that is relatively static, the proteome is extremely dynamic and 
constantly changing in response to any internal (e.g. aging) or external stimuli (e.g. toxic 
exposure). The dynamical complexity of proteins may be easily appreciated, i.e. they are 
composed of a variety of combinations of twenty amino acids, and thereafter modified co- 
and post-translationally by i.e. phosphorylation, glycosylation, and oxidation (Anderson et al. 
2001). It is these modifications that influence the activity state, folding, location, function, 
and interactions of proteins. Alterations in the expression and post-translational modification 
of proteins may have functional consequences and lead to a variety of pathophysiological 
conditions. Indeed, proteome analysis has been suggested to hold the key to improving 
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understanding, diagnosing, and treating AD, as well as to follow-up of the progression of the 
disease. 
 
The goal of proteomics is the identification and quantification of as many proteins and their 
isoforms as possible. The traditional approach in expression proteomics involves separation of 
proteins by two-dimensional gel electrophoresis (2-DE) (Klose 1975, O'Farrell 1975, 
Bjellqvist et al. 1982) followed by identification of proteins using immunoblotting or mass 
spectrometry (Henzel et al. 1993, Mann and Wilm 1994, Yates et al. 1995). In the 2-DE 
technique, proteins are separated according to their isoelectric point (pI) in the first dimension 
and then according to their molecular weight (Mr) in the second dimension. Two-dimensional 
(2-D) images are visualized and scanned followed by image analysis with specific software. It 
is possible to find differences in proteomes by comparing 2-D maps in healthy and diseased 
states. In addition to protein quantification, post-translational modifications (PTMs) may be 
studied by using slightly modified 2-DE techniques. 
 
The development of proteomics techniques to the current stage has emerged for tens of years 
(Righetti 2004). However, until very recently, there have been both technical and 
computational limitations restricting the use of proteomics, and it is still considered as a 
relatively new phenomenon in science (Hochstrasser et al. 1998, Fountoulakis 2004). 
Therefore, the present study was focused on developing clinical expression proteomic 
applications. Levels and modifications of proteins were examined in brain and cerebrospinal 
fluid (CSF), and protein profiles of AD patients were compared to those of defined controls. It 
is hoped that the present series of reports will contribute to both methodological developments 
in proteomics, as well as to deepening our understanding of the pathogenesis of AD.   
 17
2. REVIEW OF LITERATURE  
 
2.1. ALZHEIMER'S DISEASE 
2.1.1. The societal challenge 
 
Alois Alzheimer described neuropathological changes in a middle-aged woman, Auguste D, 
suffering from early-onset dementia 100 years ago (Alzheimer 1907, Maurer et al. 1997). The 
autopsy revealed the presence of peculiar protein aggregates, referred to as senile plaques and 
NFTs in the patient's brain. This disorder was named after the inventor himself as 
“Alzheimer's disease” but was long considered to be a rare disease affecting middle-aged 
individuals. It took more than 50 years to recognize that AD is also the most common cause 
of senile dementia (Blessed et al. 1968). Already in 1978, Katzman predicted that senile 
dementia of the Alzheimer type was becoming one of the most common malignant diseases 
and great challenges of our aging society (Katzman 1978). Thereupon, AD became "the silent 
epidemic' of the 20th century" and was considered uniquely as to be a problem of the 
economically advanced countries. Nowadays, AD is recognized as the most common form of 
dementia affecting an estimate of 24.3 million people worldwide, 40% of them living in less 
developed countries (Ferri et al. 2005). The prevalence of dementia in Western Europe is 
about 4.5 million, and its total annual costs amount to 55 billion euros (Andlin-Sobocki et al. 
2005, Ferri et al. 2005, Jönsson and Berr 2005). It has been estimated that the number of 
patients with dementia will double every 20 years; e.g. to 42.3 million in 2020 and to 81.1 
million by 2040 (Ferri et al. 2005). If nothing is done, an exponential increase in the costs of 
dementia will be experienced during the next few decades. As a consequence of rapid 
demographic ageing, AD has become one of the most severe progressive socio-economical 
and medical burdens facing countries all over the world. 
 
At the present time, there is no cure for AD, and the disease inevitably causes severe and 
progressive decline in daily activities, eventually resulting in institutionalisation and death. 
The pathological brain changes may occur as early as 20 to 30 years prior to the onset of 
clinical symptoms, and the symptomatic phase of AD can last from about 5 up to 12 years 
(Figure 1)(DeKosky and Marek 2003). Currently available drugs are able to delay the 
symptom progression of the disease and to positively influence the quality of everyday life of 
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patients and caregivers (Connell et al. 2001). Unfortunately, their efficacy is limited in 
magnitude and length. The treatment should be initiated as early as possible to achieve the 
best benefit. However, the diagnosis of early AD remains problematic. Moreover, the 
available drugs do not influence the progression of brain pathology in AD. Many diverse 
mechanisms are claimed to have a role in the pathogenesis of AD but their exact contributions 
remain largely unknown, and their interactions have proved tenuous, resulting in difficulties 
in discovering new therapeutic targets.  
 
 
 
 
 
 
 
Figure 1. AD is considered to be a result of a sum of complex antecedent events involving 
both genetic and environmental factors. The initial brain changes may occur decades prior to 
the onset of clinical symptoms. The first symptomatic clinical phase is called mild cognitive 
impairment (MCI). However, MCI may have several causes (i.e. normal aging, 
cerebrovascular pathology etc.) and the clinical syndrome defined as MCI does not 
necessarily mean that the patient has AD (Chong and Sahadevan 2005). Due to recent 
developments in the treatment, the diagnostic focus has shifted to the earliest phases of the 
disorder and to the detection of those MCI patients who will convert to AD. The ideal goal in 
the future would be to find interventions that prevent the development or progression of AD. 
(Modified from DeKosky and Marek 2003)   
First brain changes MCI       Progressive AD
Preclinical phase
(non-symptomatic)
Clinical phase
(symptomatic)
Age
Genes/environment
 
2.1.2 Causative and risk factors 
 
AD can be classified into early onset (<65 years) and late onset (>65 years) forms (Terry and 
Katzman 1983). Already during the 1950's, it was clear that there were families suffering 
from dominantly inherited AD, indicating that genetic factors were causing the disorder, at 
least in a small proportion of early-onset patients. Finally, at the end of 1980's, the first gene 
causing the familial early-onset AD was found (Goate et al. 1991, Price et al. 1998). It was 
located on chromosome 21 and encoded for amyloid precursor protein (APP), which is the 
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precursor protein for Aβ. This finding also explained why all patients with Down’s syndrome 
(trisomy of the chromosome 21) (DS) having chromosomal triplication and showing 
overexpression of APP gene, develop neuropathological features of AD and most of them 
become demented after 50 years of age (Schupf and Sergievsky 2002). To date, all mutations 
underlying familial autosomal dominant AD in three genes seem to influence the production 
and/or metabolism of APP and thus amyloid pathology in the brain (Rocchi et al. 2003, 
Thinakaran and Parent 2004). In addition to the APP gene, two other disease-causing genes 
are presenilin-1 and -2 on chromosomes 14 and 1, respectively (Levy-Lahad et al. 1995, 
Rogaev et al. 1995, Sherrington et al. 1995). Presenilins have been suggested to be a part of 
the γ-secretase complex and thus be crucially involved in cleavage of APP, resulting in the 
generation of Aβ peptides. Mutations in genes coding for presenilins are thought to be 
responsible for more than 80% of all familial AD cases (Rocchi et al. 2003). Interestingly, 
none of the genetic determinants for inherited AD have been directly linked to neurofibrillary 
pathology.  
 
Sporadic AD is the most common form of both early- and late-onset AD. It is considered to 
be a result of complex genetic and environmental risk factors. Apolipoprotein E (ApoE) 
polymorphism is the most thoroughly studied genetic risk factor in AD. There are three ApoE 
alleles ε2, ε3 and ε4 on chromosome 19 that result in six different phenotypes in humans 
(Zannis et al. 1981, Olaisen et al. 1982). The ε4 allele is the most important genetic risk factor 
for sporadic AD in all ages and most races, whereas ε2 is thought to be protective for the 
disease (Corder et al. 1993, Raber et al. 2004). The ApoE ε4 allele has been suggested to 
result in earlier onset of AD when compared to other phenotypes, and to be related to more 
pronounced Aβ, and neurofibrillary pathology (Polvikoski et al. 1995, Polvikoski et al. 2001, 
Raber et al. 2004). Recent studies have also revealed several other genetic risk genes and 
chromosome locuses that contribute to the susceptibility for AD (Rocchi et al. 2003).  
 
The increased longevity now experienced by many humans does not come without a price. It 
has been accompanied by a variety of chronic and degenerative illnesses e.g. age itself is the 
major risk factor for sporadic AD. The prevalence rate is about 7% for all individuals over 65 
years of age, although the risk of AD increases exponentially with age (Rocca et al. 1991, 
Breteler et al. 1992, McDowell 2001). Women, including female ApoE ε4 carriers, have been 
suggested to be at a higher risk for developing AD than men (Jorm et al. 1987, Payami et al. 
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1996, Bretsky et al. 1999, Turner, 2001). The impact of hormones on the pathogenesis of AD 
is not well understood i.e. the claims for beneficial effects of postmenopausal estrogen 
replacement therapy as a protective factor for AD remain highly controversial (Tang et al. 
1996, Zandi et al. 2002, Mulnard et al. 2004, Almeida and Flicker 2005)  
 
Elevated blood pressure and serum cholesterol in middle-age have been recently recognized 
as modifiable vascular risk factors for AD (Kivipelto et al. 2001, Kivipelto et al. 2002). They 
are known to be involved in vascular disorders (i.e. atherosclerosis, cardiovascular and 
cerebrovascular disease, type II diabetes) that are also considered to increase the risk of 
developing AD. Brain infarcts lower the threshold for clinical symptoms (Snowdon et al. 
1997) and they also seem to influence the development of AD brain pathology (Jellinger 
2004). Head trauma is considered as a risk factor for clinical AD, particularly if it occurs in 
close proximity to the beginning of the clinical symptoms (van Duijn et al. 1992, Plassman et 
al. 2000). It is possible that this association is due to similar threshold effect as hypothesized 
for brain infarcts, although experimental studies have shown that head injury influences APP 
metabolism (Uryu et al. 2002).  
 
Use is fundamental for the development and maintenance of brain functioning. The saying 
“use it or lose it” refers to the necessity of action in protection of our brains from harmful 
effects of various factors. For example, a low level of education and a passive life style are 
considered to predispose an individual to AD (Stern et al. 1994, Qiu et al. 2001). In addition, 
loneliness and history of depression are possible risk factors for AD and cognitive decline 
(Speck et al. 1995, Berger et al. 1999, Jorm 2000, Tilvis et al. 2004). Both of these 
characteristics are closely associated with each other and with aging. In contrast, a rich social 
network and many leisure activities are considered to be protective for AD (Fratiglioni et al. 
2004). The risk of AD may also be diminished by diet, moderate alcohol consumption and 
avoidance of vitamin deficiency (Letenneur 2004, Luchsinger and Mayeux 2004). Indeed, 
lifestyle does seem to matter, and it may be possible to avoid or postpone the onset of AD by 
taking care of both mental and physiological activities to sustain systemic health.  
 
Infectious agents have been suspected to contribute to cognitive impairment in the elderly as 
well as to AD. Some postmortem studies have detected signs of Chlamydia pneumoniae and 
herpes simplex type 1 virus (HSV-1) more often in AD brain as compared to control patients 
(Balin et al. 1998, Itzhaki et al. 2004, Mattson 2004a). In 2004, Strandberg et al., examined 
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bacterial and viral seropositivity among 383 home-dwelling elderly individuals. No 
significant associations were observed between bacterial burden and cognition, not even for 
Chlamydia pneumoniae. However, viral burdens of cytomegalovirus, HSV 1- and -2 were 
associated with cognitive decline. In addition, other factors such as hypothyroidism, metals, 
pesticides and electromagnetic fields have been suggested to be risk factors for AD but these 
associations need to be replicated (Brown et al. 2005).  
 
2.1.3. The pathogenetic puzzle of AD 
 
As was already described one century ago, AD brains are characterized by the presence of 
extracellular deposits of Aβ containing plaques and intracellular NFTs composed of paired 
helical filaments of hyperphosphorylated tau protein (PHF-tau). It has become obvious that 
these changes are not specific for AD and are also found in brains of cognitively unimpaired 
individuals (Davis et al. 1999, Gold et al. 2000, Riley et al. 2002). Other central pathological 
abnormalities are gliosis, chronic inflammatory reactions, excitotoxic damage, and oxidative 
stress that all appear to be involved in neurodegenerative processes occurring in the AD brain 
(Figure 2). Extensive research conducted over decades has failed to pinpoint the key 
processes resulting in neuronal death, synaptic loss and finally in the symptoms of AD. 
Research into AD can be likened to inserting random pieces into an enormous jigsaw hoping 
that the actual picture will emerge sometime in the future. 
 
2.1.3.1. The amyloid cascade hypothesis 
 
APP is a ubiquitously expressed transmembrane glycoprotein that is produced by neurons, 
astrocytes and microglia in the central nervous system (CNS) (Kang et al. 1987, Weidemann 
et al. 1989, LeBlanc et al. 1996). There are a total of eight isoforms of APP, arising from 
alternative splicing (Hartmann et al. 1996). The three major isoforms of APP vary in size 
containing 695, 751 or 770 amino acids. APP 695 is the isoform mostly present in neurones 
(LeBlanc et al. 1991), with the major difference as compared to the other isoforms, of not 
having a serine protease inhibitor domain (also called as Kunitz protease inhibitor domain). 
The proposed physiological functions of APP include regulation of neuronal survival, 
synaptic plasticity and cell adhesion (Mattson 2004b).  
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Figure 2. Schematic and simplified representation of the main pathogenetic events in AD
including plaque formation, neurofibrillar pathology, gliosis, inflammation, excitotoxicity and
oxidative stress. All complement each other and are undoubtedly involved in the vicious circle
of the pathogenesis to synaptic dysfunction eventually leading to cell death. (Modified from
Pereira et al. 2005) 
Aβ, amyloid-beta; AM, activated microglia; APP, amyloid precursor protein; ER, endoplasmic
reticulum; NFT, neurofibrillary tangle; NMDAR, N-methyl-D-aspartate receptor; P-tau,
hyperphosphorylated tau; RA, reactive astrocytes; ROS, reactive oxygen species  
 
The processing of APP and the formation of Aβ plaques are well characterised and involve a 
series of enzymes called α-, β-, and γ-secratases (Nunan and Small 2000). APP matures 
through the secretory pathway. It is post-translationally modified in the endoplasmic 
reticulum (ER) by N-glycosylation, and in Golgi apparatus by O-glycosylation (Cook et al. 
1997, Katayama et al. 2004). Cleavage of APP occurs on the plasma membrane when it is 
transported to or from the cell surface via either secretory or endocytic pathways (Hartmann 
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1999). The cleavage of APP by α-secretase occurs in the middle of Aβ-peptide and leads to 
the generation of non-amyloidogenic fragments of APP. In contrast, the cleavage of APP by 
β-secretase followed by γ-secretase creates potentially amyloidogenic peptides that are 
released into extra- or intracellular space (Mattson 2004b).  
 
The most common amyloidogenic Aβ-peptides contain 40 or 42 amino acids depending on 
the γ-cleavage. Both are formed during normal metabolism but Aβ42 is considered to be more 
critical and to be overproduced in AD (Haass et al. 1992, Younkin 1995). Aβ42 aggregates 
more rapidly as compared to Aβ40 (Burdic et al. 1992, Irie et al. 2005). The initial 
parenchymal extracellular non-filamentous deposits of Aβ are composed mainly of Aβ42. As 
the deposits grow, Aβ40 starts to aggregate onto Aβ42 deposits. Diffuse and neuritic plaques 
(NPs) are the two major amyloid deposit types in AD brain. Diffuse plaques contain mainly 
nonfibrillar amyloid. Further developed NPs contain dense bundles of amyloid fibrils and are 
surrounded by dystrophic neurites, astrocytes and microglia. Other components associated 
with plaques include serum amyloid P, α1-antichymotrypsin, sulphated glycosaminoglycans, 
α1-antitrypsin, apolipoproteins E and D, and the neurotrophic factor midkine (Desai et al. 
2005, Frey et al. 2005). 
 
The role of amyloid deposits in brain as the triggering factor for AD has been extensively 
studied since its characterisation in 1984 (Glenner et al. 1984). However, this “amyloid 
cascade hypothesis” was challenged by the fact that plaques are also found in brains of 
cognitively unimpaired elderly people (Keller 2006). Despite considerable effort, there seems 
to be no correlation between the extent of plaques and the severity of cognitive decline (Nagy 
et al. 1995, Neve and Robakis 1998). In addition, Aβ deposition is not necessarily 
accompanied by neurogeneration, and vice versa (Suh and Checler 2002). It has now become 
acknowledged that protein aggregates alone are not sufficient to cause neurodegeneration, and 
that the protein aggregates may even be protective against other harmful events in brain. 
Currently, the “amyloid cascade hypothesis” has evolved into the “Aβ cascade hypothesis”, 
which suggests that soluble Aβ oligomers, Aβ-derived diffusible ligands (ADDLs) and Aβ 
protofibrils, and their intraneuronal accumulation, play crucial neurotoxic roles in the 
pathogenesis of AD (Hardy and Selkoe 2002, Klein 2002, Golde 2003) (Figure 2). The recent 
evidence suggests that these soluble Aβ intermediates are involved in causing synaptic 
dysfunction, which may be an early event in memory decline and AD (Pereira et al. 2005). 
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“The Aβ cascade hypothesis" as the primary trigger is supported by the facts that all known 
mutations causing familiar AD target APP processing and that plaque formation has also been 
estimated to be a relatively early event in AD brain. Additional evidence has been found by 
examining a Swedish family having the “Arctic” mutation that causes atypical AD. These 
patients have decreased plasma levels of both Aβ40 and Aβ42, and less severe cerebral 
amyloid angiopathy, but their clinical features resemble aggressive early-onset AD. In 
particular, the formation of soluble protofibrils is enhanced by “Arctic” mutation, leading to 
accelerated intracellular accumulation of Aβ. “Arctic” mutation may help to confirm the role 
of the "Aβ cascade hypothesis", and Aβ oligomerisation in the early pathogenesis of AD 
(Nilsberth at al. 2001). 
 
Despite the evidence supporting the role of “Aβ cascade hypothesis” in the pathogenesis of 
AD, there are also data arguing against amyloid alone causing AD. For example, transgenic 
mouse models bearing familiar AD mutations do not show evidence of significant neuronal 
loss, excessive tau phosphorylation or tangle formation (Suh and Checler 2002). There are 
also studies that have failed to demonstrate the toxicity of Aβ in vivo and in some culture 
conditions Aβ has even promoted neurite outgrowth (Suh and Checler 2002). The clinical 
picture and the morphological end-stage in the brain appear to be the same in familiar and 
sporadic AD. Even though there is an extensive body of evidence supporting the role of Aβ in 
AD, especially in its familiar forms, the etiology of AD, particularly that of the sporadic form, 
remains unresolved.  
 
2.1.3.2. From tau to neurofibrillary tangles 
 
Tau is a phosphoprotein that is mainly synthesized by neurons but which is also present in 
astrocytes and oligodendrocytes in brain, and in peripheral tissues (Kosik et al. 1989, 
Papasozomenos 1989). Tau is coded by a gene located on chromosome 17 and alternatively 
spliced into six isoforms ranging from 352 to 441 amino acids in length (Brandt et al. 2005, 
LaFerla and Oddo 2005). Tau is the major microtubule-associated protein promoting the 
assembly and stability of microtubules, which play vital structural and functional roles in 
neurons. The main difference between the six isoforms is due to the presence of three or four 
repeats of domains that are important in microtubule binding. It is now three decades ago 
when tau was first identified to be the protein facilitating microtubule assembly (Weingarten 
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et al. 1975). Since that discovery, little interest was paid on tau until the middle of 1980’s 
when it was found to be the major protein present in PHFs that make up NFTs in AD 
(Grundke-Iqbal et al. 1986a, Grundke-Iqbal et al. 1986b, Kosik et al. 1986). 
 
Tau is functionally regulated by phosphorylation, and in its phosphorylated form cannot 
stabilise microtubules (Lee et al. 2005). Tau is a remarkable phosphoprotein since it has about 
30 potential phosphorylation sites (Geschwind 2003). The longest isoform has been suggested 
to have phosphorylations attached to up to 20% of all amino acids (Stoothoff and Johnson 
2005). In AD, tau is hyperphosphorylated, aggregated into PHFs and NFTs inside the neurons 
(Figure 2), and as a consequence, microtubules can no longer be stabilised by tau. When the 
neuron dies, NFTs become extracellular ghost tangles. Tau phosphorylation has been 
suggested to play a key role in AD pathogenesis since it has been shown to correlate with the 
severity of dementia. In 1991, Braak and Braak proposed a model of pathological evolution of 
AD. According to this model, NFTs appear in the entorhinal cortex during the preclinical 
phase, spreading to hippocampus in the middle phase and, finally, progress to the neocortex 
during the late stages of AD (Braak and Braak 1991b).  
 
Although NFTs are a characteristic hallmark in AD brain, these intracellular aggregates have 
been proposed to be a secondary process in the pathogenesis. Some studies suggest that tau is 
not required for normal cell function, and that neurons may survive with NFTs for more than 
20 years (Lee et al. 2005). The underlying event that leads to hyperphosphorylation has been 
suggested to be a result of an imbalance between the activities of kinases and phosphatases 
although the actual mechanisms remain very obscure. There is evidence that phosphatase 
activity may be deficient in AD (Gong et al. 1993, Gong et al. 2004). Another hypothesis 
suggests that an increase in oxidative stress results in activation of kinases resulting in 
hyperphosphorylation of tau (Zhu et al. 2000, Lee et al. 2005). Phosphorylated tau is 
vulnerable to oxidative stress and becomes carbonylated followed by rapid aggregation. 
Notably, tau phosphorylation has been suggested to be protective for cell survival during 
increased oxidative stress in AD. Other studies suggest that tau is essential for Aβ aggregation 
(Pereira et al. 2005). 
 
NFTs are found in cognitively unimpaired elderly individuals (Price and Morris 1999) and in 
a number of other “tauopathies” including DS, progressive supranuclear palsy, corticobasal 
degeneration, and frontotemporal dementia as well as in other neurodegenerative diseases 
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such as Parkinson’s disease. Mutations in the gene coding for tau are causative for 
frontotemporal dementia with parkinsonism (FTDP-17) (Buée et al. 2000). 
 
2.1.3.3 Gliosis and chronic inflammation 
 
In 1910, another pioneer of AD research, Oskar Fisher, failed to prove his hypothesis of 
inflammatory reactions being involved in the pathogenesis of senile dementia (Fisher 1910, 
Stuchbury and Münch 2005). One of the reasons may have been that brain has traditionally 
been considered as an immunologically privileged organ and Fisher was unable to detect any 
typical signs of inflammation. Today, it has become clear that CNS possesses an extensive 
immune system although it is quite different from that in the periphery i.e. brain does not 
exhibit "the four cardinal signs" of peripheral inflammation; calor (heat), rubor (redness), 
tumor (swelling), and dolor (pain) (McGeer and McGeer 2001). Inflammatory reactions in 
CNS are mainly mediated by brain-specific glial cells, notably by microglia and astrocytes, 
and to a lesser degree by neurons. Under physiological conditions, glial cells support and 
protect neurons and their functions, and have many critical roles in the homeostasis and 
activity of the brain (Tuppo and Arias 2005). In AD, inflammation has recently been 
confirmed as an essential feature, particularly in association with neuritic plaques (Figure 2). 
The inflammatory reaction is characterized by activation of glial cells, gliosis and the 
appearance of inflammatory proteins such as complement factors, acute phase proteins, and 
proinflammatory cytokines (Akiyama et al. 2000).  
 
In brain, microglial cells are considered to represent the equivalent of monocytes and 
macrophages (Ling and Wong 1993, Rock et al. 2004). Under normal conditions, microglial 
cells exist in a resting stage, where they are inactive, and show low expression of surface 
receptors, secretory activity, proliferatory and phagocytic function, and minimal migration 
(Giulian et al. 1995, Färber and Kettenmann 2005). Microglia is the first cell population 
showing activity in response to any kind of insult in brain such as trauma, infection or 
inflammation. Activated microglia (AM) do not only exhibit phagocytic and scavenger 
activities but also release reactive oxygen species (ROS), nitrogen compounds, excitatory 
amino acids (i.e. glutamate), proteases and cytokines (i.e. interleukins (IL) -1, -6, tumor 
necrosis factor alpha), and macrophage colony stimulating factor (Akiyama et al. 2000, 
Blasko et al. 2004). AM are characterised by their increased expression of human leukocyte 
antigen (HLA-DR), a class II major histocompatibility complex (MHC) cell-surface antigen. 
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 Astrocytes are the most common cells found in the brain. Until recently, they were thought to 
be mostly rather passive and solely involved with connective tissue and skeletal function in 
the brain. They were known to participate in the formation and maintenance of the blood-
brain-barrier (BBB) that isolates the brain from peripheral influences and protects it from a 
number of inflammatory factors (Ballabh et al. 2004). Molecules that are small or highly 
lipophilic can pass into the CNS under normal physiological conditions. Today, it has become 
evident that astrocytes play an active role in the functioning of brain although their complete 
contribution has yet to be revealed. Under physiological conditions, astrocytes regulate 
extracellular pH and ion levels, take up and detoxify harmful compounds such as amino acids 
(i.e. glutamate-glutamine cycling), ammonia, free radicals and xenobiotics (Blasco et al. 
2004). In addition, astrocytes are involved in neuronal migration, neurite outgrowth, synaptic 
plasticity, modulation of inflammatory responses and the formation of glial scars (Norenberg 
1994). During inflammation, AM can activate astrocytes (i.e. by secreting IL-1 and -6), which 
are then transformed into reactive astrocytes (RAs). During gliosis, RAs increase in size 
and/or number, and are characterised by overexpression of glial fibrillary acidic protein 
(GFAP) (Eng et al. 2000, Eikelenboom and Van Gool 20004). 
 
The role of inflammation in neurodegenerative diseases remains controversial since it may be 
both neuroprotective and neurotoxic, like a double-edged sword (Marchetti and Abbracchio 
2005). Inflammation is almost always a secondary desirable response to a primary injury. 
However, when inflammation becomes chronic in its nature, it will likely evoke more damage 
than the initial injury. Both AM and RAs are found to be associated with Aβ depositions in 
AD brain (Nagele et al. 2004) (Figure 2). It has been hypothesised that Aβ is indirectly toxic, 
activating microglia to produce neurotoxins including ROS and cytokines that further activate 
astrocytes. Activated glial cells are classically thought to remove and degrade Aβ depositions 
in AD brain (De Felice and Ferreira 2002, Nicoll and Weller 2003, Streit 2005). However, the 
homeostatic control may fail and the clearance of Aβ may become altered in AD patients. As 
a consequence, the crosstalk between neurons, astrocytes and microglia may become 
disturbed. Thus, inflammation may contribute to neurodegeneration via increased oxidative 
stress and neuropathological changes.  
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2.1.3.4. Excitotoxicity 
 
Excitotoxicity is also considered to play an important role in the pathogenesis of AD. It is 
triggered by excessive stimulation of glutamate receptors (e.g. N-methyl-D-aspartate also 
known as NMDA) due to either increased release or decreased uptake of excitatory amino 
acids, mostly glutamate (Hynd et al. 2004) (Figure 2). As a result, perturbations occur in 
cellular ion homeostasis (Ca2+, K+, Na+) and metabolic activities. The most crucial 
disturbance is considered to be the overload in the intracellular level of Ca2+ that may 
originate from the extracellular space and/or ER, resulting in diverse neurotoxic effects due to 
calcium dysregulation and alterations in Ca2+-signaling pathways (Siesjö 1981, Paschen 
2000). Calcium dysregulation may also be caused by ER stress, which is characterized by 
inhibition of protein glycosylation and an increase in unfolded proteins in the ER (Katayama 
et al. 2004, Schröder and Kaufman 2005). Under pathological conditions, an increase in 
intracellular calcium results in overload of Ca2+ in mitochondria, causing mitochondrial 
dysfunction manifested by increased production of ROS, decreased energy metabolism, 
release in cytochrome c, and eventually apoptosis (Rego and Oliveira 2003). In brain, calcium 
dysregulation is considered to be capable of eliciting increased Aβ formation and tau 
phosphorylation (LaFerla et al. 2002, Pereira et al. 2005). It must be remembered that calcium 
dysregulation, ER stress, mitochondrial dysfunction, and defective energy metabolism may 
also be initiated by other factors that are unrelated to excitotoxicity. 
 
2.1.3.5. Oxidative stress and accumulation of redox-active metals 
 
The free radical theory of aging was first presented by Harman in 1956. Aging was described 
as a progressive, inevitable process partially related to the accumulation of biomolecules 
damaged by radiation. Oxidative damage of biological systems occurs when the production of 
oxygen radicals and ROS exceeds the cell's antioxidant capacity, leading to oxidative 
imbalance in a system (Figure 3) (Dalle-Donne et al. 2003a, Mariani et al. 2005). The main 
intracellular source of ROS is the electron transport chain in the oxidative phosphorylation 
processes occurring within mitochondria, which is the “energy factory of the cell”. Moreover, 
deterioration of mitochondria itself, as a consequence of oxidative stress, is thought to play a 
key role in aging processes (Miquel et al. 1980; Sastre et al. 2003). The main cellular source 
of ROS in the brain is AM, linking oxidative stress closely with inflammatory processes. The 
brain is considered to be particularly vulnerable to the deleterious effects of ROS since the 
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CNS consumes high amounts of oxygen to produce energy. In addition, the brain contains 
high amounts of polyunsaturated fatty acids that are susceptible to lipid peroxidation, as well 
as metals that can catalyse the reactions leading to the production of ROS. Furthermore, the 
brain is thought to have a relatively low antioxidant capacity (Mariani et al. 2005). 
 
ROS Antioxidant defence enzymes Antioxidants
OXIDATIVE STRESS
Adaptation by upregulation of 
defence system
Oxidative damage to DNA, RNA, 
carbohydrates, lipids and proteins
Complete protection
against damage
Incomplete or no 
protection
against damage
Various consequences:
Calcium dysregulation
Excitotoxicity
Mitochondrial dysfunction
ER stress
Aggregation of proteins
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etc.
Neutralisation
of oxidative stress
Cell survival
NO DISEASE
Cell death
DISEASE
 
Figure 3. Oxygen is both necessary and toxic to organisms living in an aerobic environment. 
Oxidative stress plays a central role in both "normal aging" and in the pathogenesis of AD. 
Origins of oxidative stress in aging and disease arise from a failure of an organism to adapt to 
increased production of ROS and/or diminished antioxidant defence systems. Oxidative stress 
may have a variety of functional consequences that lead to cell death. (Modified from Dalle-
Donne et al. 2003a) 
ER, endoplasmatic reticulum; ROS, reactive oxygen species. 
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The concept of oxidative stress in AD was originally derived from the free radical theory of 
aging. In the last 10 years, an increasing number of studies have been published reporting a 
variety of results on the role of oxidative stress in AD (Praticò 2005). There is evidence of 
increased oxidation of DNA, RNA, protein, lipids and carbohydrates in AD brain (reviewed 
by Sayre et al. 2005). Oxidative stress markers have also been found to be increased in CSF, 
blood and urine of AD patients (Irizarry 2004, Praticò 2005). In addition, oxidative stress is 
associated with altered metal ion homeostasis in AD, leading to enhanced accumulation of 
redox-active metals and thus to increased production of ROS (Atwood et al. 1999, Pereira et 
al. 2005, Sayre 2005). Accumulation of metals is also associated with enhanced aggregation 
of proteins. Although oxidative stress can be easily associated with other pathological features 
of AD, it has been considered as being secondary to the pathogenesis. Oxidative stress is 
clearly an important neurodegenerative element that contributes to neuronal loss, and 
therefore plays a crucial role in disease processes. Furthermore, oxidative damage is also 
considered to be one of the earliest signs in AD but then to decrease with disease progression 
and NFT formation (Nunomura et al. 2001, Praticò et al. 2002, Lee et al. 2005). Additionally, 
protein aggregation, including Aβ, has been suggested to be protective against increased 
oxidative stress. 
 
 
2.1.3.6. Other pathological features   
 
Synaptic dysfunction in the absence of loss of synapses and neuronal cell death has been 
suggested to be an early event in AD and to occur prior to plaque formation (Selkoe 2002, 
Pereira et al. 2005). The synaptic loss is the best current pathologic correlate of memory and 
cognitive decline (Coleman and Yao 2003). On the other hand, some studies indicate that it is 
soluble Aβ which correlates significantly with the synaptic pathology in AD (Lue et al. 1999, 
McLean et al. 1999). A variety of mechanisms appear to contribute to synaptic dysfunction 
and have diverse consequences such as alterations in synaptic proteins, membrane lipids, 
vesicular function and loss of plasticity (Coleman et al. 2004). The initial triggers may be Aβ 
toxicity or disrupted intracellular transport of aggregated tau (Pereira et al. 2005). In addition, 
excitotoxicity, oxidative stress, and apoptosis have all been claimed to contribute to synaptic 
dysfunction. 
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It is evident that the final crucial event in AD pathogenesis is cell death. In 1972, Kerr et al 
described two types of cell death called necrosis or apoptosis (Kerr et al. 1972, Sastry and 
Rao 2000). Necrosis is characterised as "passive atrophy" that is a result of injury and it is a 
process that triggers inflammation. In contrast, apoptosis is described as "active energy-
dependent degeneration" that is required for normal development and involves activation of a 
complex intrinsic cellular suicide program. Increasing evidence suggests that apoptosis is the 
major type of cell death involved in neurodegenerative disorders although inflammation is 
also involved in the pathogenesis (Loo et al. 1993, Su et al. 1994, Smale et al. 1995). In CNS, 
potential inducers of apoptosis include neurotrophic factors, changes in potassium 
concentration, calcium dysregulation, modulators of protein phosphorylation, DNA damage, 
neurotransmitters (i.e. glutamate), peptides and proteins (i.e. Αβ), oxidative stress, nitric 
oxide, lipids (i.e. retinoic acid), irradiation, and certain neurotoxins (i.e. ethanol) (Sastry and 
Rao 2000). 
 
2.1.4. Diagnosis  
 
2.1.4.1. Clinical diagnosis 
 
There is no laboratory test for the diagnosis of AD. Today, the diagnosis of AD is mainly 
based on clinical and neuropsychological findings, combined with the exclusion of other 
possible causes for dementia. The most commonly used clinical criteria were outlined two 
decades ago by the National Institute of Neurological and Communicative Disorders and 
Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) 
(McKhann et al. 1984). Patients with probable AD manifest a gradual onset and progression of 
memory and cognitive decline, and do not show signs or findings of other causes for dementia. 
In contrast, the diagnosis of possible AD is more complex and given in the presence of i) 
dementia syndrome in the absence of other neurologic, psychiatric, or systemic disorders than 
AD with variations in the typical course of the clinical picture, ii) secondary brain disorder/s 
sufficient to cause dementia although AD is suspected to be the major cause of dementia, and 
iii) gradually progressive severe cognitive deficit in the absence of other identifiable causes. 
According to NINCDS-ADRDA, the diagnosis of possible and probable AD can be confirmed 
to be definite only by neuropathological examination at either biopsy or autopsy. The 
diagnosis made by NINCDS-ADRDA has high accuracy (80-90%) according to the data 
obtained from patients with severe AD and repeated examinations (Galasko et al. 1994, 
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Kosunen et al. 1996). However, the accuracy is acknowledged to be lower when diagnosing 
patients with early stages of AD or with mild cognitive impairment (MCI), and in the absence 
of repeated examinations (Blennow and Hampel 2003). The earliest cases of AD can be found 
among individuals suffering from MCI. Currently, the most commonly used criteria for the 
diagnosis of MCI has been forwarded by the Mayo Clinic Alzheimer’s Disease Research 
Center (MCADRC) (Petersen et al. 1999, Petersen 2004, Chong and Shavadevan 2005). The 
clinical criteria for amnestic MCI (MCI with memory impairment) require the presence of 
memory complaint, objective memory impairment for age, preserved general cognitive 
function, normal functional activities, and absence dementia. However, MCI is an 
aetiologically heterogeneous condition and its prognosis varies in different studies and 
populations. Conversion rates from MCI to dementia up to 12% annually, and 80% at six 
years' follow-up have been described (Petersen 2004).  
 
The current diagnosis of AD is far from straightforward and the accuracy often varies between 
health care centers. Brain imaging, particularly magnetic resonance imaging (MRI) can 
strengthen the diagnosis of AD. The decrease in volumes of hippocampus and entorhinal 
cortex detected by MRI has been suggested to be useful in the diagnosis of AD, and even in 
predicting MCI patients who will develop AD (Laakso 2002, Chong and Shavadevan 2005). 
Still, there is a great need for an equivocal diagnostic test for AD and progressive MCI that 
could be routinely applied in laboratories. Until now, candidate biomarkers have been sought 
from the CSF of AD patients. Since 1992, a large number of research groups have examined 
the suitability of total tau, phosphorylated tau, total Aβ, Aβ40 and Aβ42 as possible 
biomarkers for AD. Consistent findings have included a reduction of Aβ42 or the ratio of 
Aβ42/Aβ40, and an increase of total and phosphorylated tau in CSF in AD patients as 
compared to controls (Blennow and Hampel 2003). Today, the best outcome in early diagnosis 
and prediction of progressive MCI has been reached by combining these Aβ and tau markers 
(Herukka et al. 2005). In general, the current tests achieve good specificity but unsatisfactory 
sensitivity (Frey et al. 2005). Nonetheless, they are suitable for routine use in specialized units. 
 
2.1.4.2. Neuropathological diagnosis 
 
As is the case with clinical diagnosis, several classifications also exist when performing 
neuropathological examinations for AD. The foundations for the currently used criteria were 
laid by Khachaturian in 1976, and were based on detecting both senile plaques of any type and 
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tangles (Khachaturian 1985). In 1991, new criteria were introduced by the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) (Mirra et al. 1991), which are based 
on the presence or absence of plaques, clinical dementia, and possibly other neuropathological 
lesions that might influence memory or cognition. CERAD divides AD into four possible 
classifications being normal, possible, probable, and definite. In 1991, Braak and Braak, 
suggested a pattern for progression of AD depending on the presence of NFTs in hippocampal 
brain regions. The severity of AD was thus assessed as entorhinal (I-II), limbic (III-IV), and 
isocortical (V-VI) stages (Braak and Braak 1991b). The most recent criteria were established 
by the National Institute on Aging- Reagan Institute (NIA) (1997), which follow the 
guidelines of both CERAD and Braak and Braak, supplemented with some additional 
immunohistochemical approaches.  
 
It is quite common that cognitively intact subjects possess sufficient levels of brain pathology 
to fulfill the criteria of AD. For example, 49% of dementia free subjects have been diagnosed 
with AD when following the Khachaturian criteria, 18-25% met the CERAD criteria for 
possible AD; and 10-12% fullfilled the NIA criteria for intermediate likelihood for dementia 
(reviewed by Keller 2006). One dilemma is the long preclinical phase in AD. Although the 
subjects are free of clinical symptoms, it is not possible to determine whether their brain 
changes are due to the preclinical phase of AD. It is unclear whether significant amyloid 
pathology can develop during disease-free aging.  
 
2.2. THE ERA OF PROTEOMICS 
2.2.1. From genome to proteome 
 
The human genome sequencing was completed in 2002. One of the most surprising findings 
in the project was that humans have hardly any more genes than a fly or a worm (Southan 
2004). As a consequence, it was recognised that human complexity cannot be solely 
explained by the genome, and the attention turned to examining the changes of proteins in a 
given genome at a given time (Anderson et al. 2001). The word proteome (=the entire 
PROTein complement expressed by a genOME, or by a cell or a tissue type at a given time) 
was first coined by Wilkins et al. in 1995 (Wilkins et al. 1996). Between individuals, the 
proteome differs not only depending on the genome but also dynamically due to any internal 
and external stimuli i.e. physiological state, health, disease, age, stress, and drugs. After 
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transcription, proteins can be modulated at many points prior to PTMs that finally determine 
the functional consequences inside the cell (Figure 4) (Banks et al. 2000). Ultimately, 
proteome analysis is like taking a photograph of the expression pattern of modified proteins 
and their isoforms at a particular time.  
 
Proteomics has become an expanding multidisciplinary technology-driven area of science 
focused on studying structures, functions and levels of proteins (Fountoulakis 2004). These 
disciplines are called structural, functional, and expression proteomics. The latter is currently 
the most advanced and most widely studied of the known disciplines in clinical proteomics 
(Aldred et al. 2004). Although proteomics as an entity is relatively new, the methodological 
and theoretical foundations have been under development for more than three decades 
(Anderson et al. 2001, Righetti 2004). Methodologically, expression proteomics aims at i) 
separation of complex protein mixtures and ii) quantification and identification of these 
proteins. Theoretically, the goal of proteomics is to study changes of multiple proteins 
simultaneously. In fact, this concept was already introduced in 1981 by Clark as "towards the 
total protein map" who forecast the separation and characterization of thousands of proteins 
simultaneously. Though there have been major methodological and theoretical developments 
in proteomics, it is still considered to be in its infancy, and to belong to so called "New 
Technologies" (Fountoulakis 2004). 
 
In the future, downstream steps after genomics and proteomics will aim at understanding 
functional consequences of biomolecule interactions in different biological pathways in a 
system. This will involve other overlapping “–omics” such as peptidomics, metabolomics, 
interactomics etc. The main goal is to understand how living organisms function as a whole. 
The knowledge of all “–omics” gathered together is called systems biology.  
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Figure 4. The complexity increases from the genetic code which is made up of four nucleic 
acids in DNA up to proteins created from twenty amino acids. The size of human genome 
consist of about 3000 megabasepairs, giving rise to an estimate of about 25 000 to 30 000 
genes (Southan 2004). Messenger RNA can be spliced in various ways but the amount of 
RNA does not necessarily correlate with the amount of active protein in a cell. The number of 
protein isoforms per gene has been estimated to be greater than ten. Moreover, after being 
synthesised, proteins are subject to a variety of modifications that take place in different 
cellular compartments including nucleus, cytosol, endoplasmic reticulum, and Golgi 
apparatus. In other words, modified proteins are the time-dependent output of a cell, and thus 
the functional output cannot be predicted from analysis of nucleic acids alone. The function 
of a protein may also vary during its lifespan; depending on modifications and cellular 
localisations i.e. proteins can be multifunctional. Despite the existence of tight regulatory 
controls, it is reasonable to assume that alterations in processes from genes to functional 
proteins may lead to a variety of pathological conditions. (Modified from Banks et al 2000)  
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Figure 5. Common workflows in two-dimensional gel electrophoresis in combination with 
immunoblotting and mass spectrometry. After preparation, samples are applied to immobilized pH 
gradient (IPG) strips by either in-gel rehydration or by cup-loading and then the proteins are 
separated according to their isoelectric points by isoelectric focusing (IEF) in the first dimension. 
Proteins on the IPG strips are reduced and alkylated, and laid on the top of a gel. In the second 
dimension, proteins are separated usually by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) according to their molecular weight. Proteins are visualised 
normally by Coomassie brilliant blue, silver staining or fluorescent dyes followed by scanning in 
order to convert the gels into a digital format. The levels and modifications of proteins on two-
dimensional (2-D) gels are then determined by image analysis. Alternatively, levels of proteins 
and selected modifications can be studied by specific stains, immunoblotting and image analysis. 
Stained proteins on 2-D gels can be cut out for in-gel digestion and identification by mass 
spectrometry and databa
Sample preparation
1st dimension: IEF using IPG strips 
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2.2.2. Proteome analysis 
 
Though there have been promising alternative and new techniques introduced into proteomics 
(Graham et al. 2005), 2-DE in combination of mass spectrometry and/or immunoblotting still 
remains the most widely used methodological approach in diffrential and quantitative 
proteome analyses. The traditional workflow usually includes i) sample preparation and 
protein solubilisation, ii) separation of proteins by 2-DE, iii) protein detection, iv) 2-D image 
analysis and quantification, v) identification of selected proteins (Figure 5). 
 
2.2.2.1. Sample preparation for electrophoresis 
 
Definition of sample material and solubilisation of proteins, are some of the most important 
steps in 2-DE. Currently, it has been emphasized that it is important to define what type and 
kind of a proteome population is intended to be studied i.e.: is it the proteome of one 
particular type of cell, a subcellular organelle, a cytosolic or a membranic fraction? 
Understandably but unfortunately, there is no single powerful method for sample preparation 
that can be applied to all kinds of samples to be analysed by 2-DE, since the chemical nature 
of proteins is extremely diverse in different tissues and localisations. The three fundamental 
steps in sample preparation are cell disruption, protein inactivation plus removal of interfering 
substances, and solubilisation of proteins of choice. Additionally, in some cases, proteins need 
to be enriched or prefractionated. It is desirable that the sample preparation should be as 
simple and reproducible as possible (Görg et al. 2004). 
 
 
2.2.2.2. Two-dimensional gel electrophoresis 
 
2-DE is based on the separation of proteins, first according to their pI in the first dimension 
and then according to their Mr in the second dimension. It has taken decades for 2-DE to 
develop as the fundamental base of proteomics. The use of polyacrylamide in 
electrophoretical separations was first introduced by Raymond and Weintraub in 1959 
whereas the basic theory of IEF in combination with carrier ampholytes (CAs) as a way to 
obtain an isoelectric distribution of proteins took place during the 1960’s (Svensson 1961, 
Vesterberg and Svensson 1966, Dale and Latner 1969).  
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In the 1970’s, the basis for the current 2-DE technology was established (Klose 1975, 
O'Farrell 1975). In the early studies, isoelectric focusing (IEF) was performed using CAs that 
have certain limitations i.e. poor reproducibility, cathodic drift and batch to batch variability. 
To overcome the limitations in conventional CAs, immobilized pH gradient (IPG) strips were 
introduced by Bjellqvist et al. in 1982. These IPG strips clearly improved the reproducibility 
and resolution of IEF. A stable pH gradient was created by using ampholyte molecules co-
polymerised in the polyacrylamide gel. One of the most beneficial features of IPG strips as 
compared to CAs is that when an electric field is applied, the gradient does not drift. In 
addition, IPG strips have proved to be easily commercialised and currently there is a great 
variety of different pH gradients available for researchers i.e. 7-24 cm long IPG strips with 
wide (i.e. pH 3-12), medium (i.e. pH 4-7), narrow (i.e. pH 5.5-6.5) and ultra-narrow (i.e. pH 
4.9.-5.3) pH ranges (Görg et al. 2000, Görg et al. 2004). Despite the technical improvements 
in IEF thanks to introduction of IPG strips, they have not supplanted conventional CAs that 
are still successfully used in several laboratories. To date, the largest 42 x 33 cm 2-D gels 
have been made using CAs and, remarkably, more than 10 000 polypeptides can be detected 
(Klose and Zeindl 1984). In addition, carrier ampholyte-based IEF still possesses several 
technical advantages as compared to IPG strips such as high tolerance to chemicals used for 
solubilisation of proteins and, thus it is more suitable for studying i.e. hydrophobic and 
membrane proteomes. 
 
The latest innovation in 2-DE was the development of the differential in-gel electrophoresis 
(DIGE) technology (Ünlü et al. 1997, Lilley and Friedman 2004). It is based on labelling 
proteins with fluorescent Cy2, Cy3, and Cy5 dyes. All of these dyes have identical Mr and pI 
but differ in excitation and emission wavelengths. Therefore, up to three different protein 
mixtures can be labelled individually but separated and analyzed on a single gel. After 
scanning one gel, three separate images are obtained. The major advantages when considering 
clinical proteomics are that an internal protein standard may be labelled with one of the dyes, 
leading to better control of gel to gel variation and thus to better quantitative and qualitative 
image analysis of proteins.  
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2.2.2.3. Image analysis 
 
One of the several reasons why 2-DE has become popular in clinical expression proteomics 
during the last decade has been the development of algorithms for convenient data acquisition 
to be able to compare 2-D maps and to quantify the proteins. Already in 1975, O’Farrell 
detected about 1100 E.coli proteins on 2-D images (O'Farrell 1975, Righetti 2004). 
Obviously, the analysis of the proteins by eye was comparable to looking at stars on the sky. 
The development of the first image analysis software began during the 1980's (Righetti 2004), 
and since then these programs have continuously improved. Currently, there are several 2-D 
image analysis software packages commercially available. However, the existing programs 
still need to be improved into faster and more automated analyses that do not require manual 
interventions by the user (Görg et al. 2004). The traditional workflow in image analysis 
includes spot detection, matching of proteins to corresponding spots on a reference gel, 
background subtraction, and quantification.  
 
2.2.2.4. Protein identification by mass spectrometry 
 
The new era in proteomics began during 1990's also thanks to the development of mass 
spectrometry (MS) techniques as well as the appearance of sequence databases on the World 
Wide Web. In electrophoresis-MS-based identification, proteins are first separated 
electrophoretically and excised from gels followed by proteolytical in-gel digestion e.g. with 
trypsin. The resulting peptides are analysed by MS and the proteins identified by database 
searches (Thiede et al. 2005).  
 
The breakthrough in biological MS took place in the late 1980's in conjunction with the 
invention of electrospray ionization (ESI) (Fenn et al. 1989) and matrix-assisted laser 
desorption/ ionization (MALDI) (Tanaka et al. 1988, Karas and Hillenkamp 1988). The 
discovery and development of these currently widely used two ionization methods was 
recognized by the award of the 2002 Nobel Prize in Chemistry. ESI ionizes analytes out of 
solution and is often coupled to a liquid separation tool such as liquid chromatography (LC). 
MALDI is based on laser pulses bombarding samples mixed with matrix, attached to a steel 
probe, leading to desorption and ionisation of the peptides. A mass spectrometer consists of 
either ESI or MALDI ion source coupled to an analyser/s. There are several different types of 
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analysers that are all very different from each other, with their own strengths and weaknesses 
(Yates 1998, Aebersold and Mann 2003). 
 
Protein identification can be divided into two categories: peptide mass analysis and partial 
peptide sequencing (Yates 1998). The simplest and fastest way to identify proteins is still 
considered to be the peptide mass fingerprinting (PMF) also called mass analysis. In PMF, the 
experimentally obtained masses of peptides are matched with the theoretical peptide masses 
generated from protein sequences stored in databases. Robust and high-throughput MALDI in 
combination with a time-of- flight (TOF) analyser is often used for PMF with a limitation that 
it can only handle quite simple peptide mixtures i.e. proteins isolated from a 2-D gel. In 
contrast to PMF, peptide sequencing using tandem MS (MS/MS), can be applied to identify 
proteins in more complex mixtures. In addition to peptide masses, the MS/MS spectra gives 
information about a part of the amino acid sequence of the peptide. LC-ESI-MS/MS is often 
used for peptide sequencing. 
 
 2.2.2.5 Gel-free proteome analysis 
 
Although IPG-based 2-DE is currently the most commonly used technique in expression 
proteomics, and has recently experienced methodological improvements including DIGE 
technology, it is still time- and labour-consuming, and suffers from several limitations. 
Therefore, researchers are trying to develop quantitative proteomics methods towards 
alternative more automated, high-throughput, and gel-free systems (David et al. 2005, 
Graham et al. 2005, Schmidt et al. 2005). The most promising new gel-free systems that have 
been developed are based on LC-MS applications. Traditionally, these applications are able to 
answer the question: which proteins are present in a sample, but not: how much of a protein is 
in a sample (Reinders et al. 2004). In order to be able to obtain relative abundances of 
proteins in a sample using gel-free MS-based technical approaches, novel techniques for 
stable isotope protein labelling (i.e. by using isotope-coded affinity tagging of proteins called 
ICAT or peptides using iTRAQTM) have been introduced recently (Schneider and Hall 2005). 
Generally, in these approaches, two or more samples are labelled with distinguishable 
chemically identical reagents having slightly different molecular weights, proteins are 
digested, separated, and analysed by MS. The labelled peptides in each sample have defined 
size difference in their masses leading to analysis of quantitative differences of proteomes 
between groups. Moreover, proteins can be identified from MS/MS data or peptide 
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sequencing. There are also other approaches that may be able to resolve some of the problems 
in differential 2-DE i.e. antibody arrays and surface enhanced laser desorption ionization 
time-of-flight mass spectrometry (SELDI-TOF-MS) (Davis et al. 2005). Despite overcoming 
a number of problems in proteomics, none of the new approaches can yet substitute for 2-DE 
in separating and quantifying proteins in terms of the numbers of proteins, followed by robust 
and reliable identification by MS. In other words, there is no single powerful method in 
proteomics since all techniques are still considered to be complementary to each other. 
 
 
2.2.2.6. Detection of protein modifications  
 
The analysis of protein modifications represents a challenging task in clinical research. 
Modifications may be structurally extremely heterogeneous i.e. glycosylations where there are 
many carbohydrates that are difficult to analyze (Reinders et al. 2004). They can also be 
highly unstable e.g. as in the case of phosphorylation, which is an important modification 
involved in the activation and deactivation of about 50% of all proteins (Reinders and 
Sickmann 2005). 
 
Some modifications can be deduced by examining protein patterns on a stained 2-DE gel or a 
membrane. For example, in 2-DE, phosphorylation and glycosylation are known to affect the 
charge carried by the proteins leading to a pearl-like horizontal trail of protein spots, and they 
may also affect the size of the protein (Mann and Jensen 2003). There are several 
commercially available staining kits and antibodies that can be used to stain or detect 
specifically modified proteins, respectively (Talent et al. 1998, Kaufmann et al. 2001, Patton 
2002). Proteins can also be enriched based on the affinity of the modifications prior to 
analysis i.e. by using lectins to separate glycoproteins (Hage 1999, Mann and Jensen 2003). 
Alternatively, proteins can be separated by 2-DE before and after the enzymatic removal of 
the modifications (Mann and Jensen 2003). "Disappearing" groups indicate the presence of 
modified proteins.  
 
If modifications of intact proteins are to be studied on a large-scale in more detail, 2-DE in 
combination with other methods is currently the approach of choice. Moreover, a multiplexed 
proteomics platform has recently been introduced and allows the parallel determination of 
levels and modifications of proteins. The multiplexed proteomics technology utilizes 
fluorophores with different emission and/or excitation wavelengths to study multiple targets 
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on a single gel or a membrane (Patton 2002). Modifications of proteins and their sites on the 
peptide backbone can be studied by a variety of traditional MS approaches but the protein 
usually needs to be isolated and digested prior to analysis. However, the levels and 
modifications of multiple proteins can be studied after digestion using MS-based stable 
isotope protein labelling technologies (i.e. ICAT or iTRAQTM) but these large-scale 
approaches still remain troublesome partially due to the lack of sophisticated software and 
databases for data analysis. 
 
2.3. 2DE-BASED EXPRESSION PROTEOMICS AND AD  
2.3.1. Protein changes 
 
Even if expression proteomics is still considered to be methodologically in its infancy, the 
technology has been claimed to represent an efficient tool in finding new biomarkers or a 
panel of markers for more accurate diagnosis of complex human diseases. Until now, most 
efforts in screening for new biomarker candidates have been concentrated in cardiovascular, 
infectious, and neurological disorders as well as in several types of cancers (Banks et al. 
2000). When considering neurological disorders, one good example for the usability of 2-DE 
in exploring new biomarkers, was the discovery of two unknown protein isoforms p130 and 
p131 that were suggested to be able to discriminate Creutzfeld-Jakob disease from other types 
of dementia (Harrington et al. 1986). Subsequently, these proteins were identified as 14-3-3 
proteins and further studies confirmed the usefulness of this finding. Notably, the 
measurement of 14-3-3 has now been included in the diagnostic criteria of Creutzfeld-Jakob 
disease (Zerr et al. 2000, Ingrosso et al. 2002). Expression proteomics has also been suggested 
to be the solution in improving the diagnosis of AD, even in its early stages, as well as to 
enable the follow-up of the progression of the disease. AD has clearly been one of the major 
focuses of research in this field. Yet, the current findings represent the tip of the iceberg in the 
search for diagnostic markers and uncovering the secrets of AD pathogenesis.  
 
2.3.1.1. Brain 
 
Most efforts in understanding the pathogenesis using 2-DE-based expression proteomics have 
been made by comparing brain proteomes of AD patients and controls. Some of the first 2-DE 
studies examined the levels of AD brain proteins (Comings 1982c, Comings 1982b, Comings 
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1982a, Smirnov et al. 1991, Burbaeva 1992, Mattila and Frey 1994). Initial studies revealed 
alterations in the levels of a number of proteins i.e. GFAP, tubulin, and creatine kinase. 
Subsequently, the number of 2-DE studies has multiplied and at present changes in the levels 
of more than 100 brain protein isoforms have been identified in neurodegenerative disorders 
(Butterfield et al. 2003, Fountoulakis 2004, Vercauteren et al. 2004). Despite the multiplicity 
of isoform specific protein changes, the findings still remain rather fragmented, for example, 
they have not revealed unified or even novel hypothesis related to the pathogenesis of AD. 
 
2.3.1.2. Cerebrospinal fluid 
 
Although the brain is the target organ in AD, it is obvious that post-mortem studies have 
several drawbacks which complicate any elucidation of the pathology in living patients. CSF 
is considered as a window into brain metabolism since it is in contact with extracellular space 
in brain, and thus its contents partially reflect cerebral metabolic changes. Approximately 
20% of CSF proteins are derived from brain. The first work on 2-D distribution of CSF 
proteins in AD was carried out already 1973 by Latner but the methodology in use then was 
very different from the current 2-DE (Dale and Latner 1969). Later, several of the early 2-DE 
studies failed to identify AD-specific changes in the CSF proteome (Harrington and Merril 
1984, Harrington et al. 1985, Alafuzoff et al. 1986, Harrington et al. 1986, Townsend et al. 
1987). In the early 1990's, an isoform of haptoglobin-alpha-1 chains was found to be present 
in the majority of 2-D maps in AD vs. age-matched controls. These findings were considered 
to reflect an altered blood-brain-barrier function in AD (Mattila et al. 1994). Recent studies 
have reported various differences in the CSF proteome by comparing AD patients and 
controls (Hesse et al. 2001, Choe et al. 2002, Davidsson et al. 2002, Puchades et al. 2003). In 
the studies of Davidsson et al. 2002 and Puchades et al. 2003, a large number of protein 
isoforms with altered levels were identified in AD. One common finding in these studies was 
that the levels of most proteins tended to be decreased in AD vs. controls although some 
proteins showed increased levels. These findings may reflect brain pathology since several of 
the identified proteins are involved in inflammatory events and, are known to be associated 
with the protein aggregates present in the AD brain.  
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2.3.1.3. Blood 
 
Although the lumbar puncture needed to obtain CSF is relatively safe, it is still an invasive 
and painful procedure that is not routinely performed, except in specialized centres involved 
in research trials. An increasing amount of evidence has revealed numerous abnormalities in 
peripheral tissues e.g. in blood and skin cells in AD (Blass and Zemcov 1984, Scott 1993). 
Therefore, some studies have focused on the possible AD-specific proteome changes in blood 
and other peripheral tissues. The first 2-DE study of peripheral changes in AD identified an 
abnormal expression of actin in lymphocytes (Jabbour et al. 1992). Thereafter, variations in 
the proteomes of red blood cell membrane, platelets and lymphocytes were detected between 
AD patients and controls (Mattila and Frey 1995). One of the proteins consistently identified 
was the cytoskeletal protein, actin, which exhibited reduced levels in AD platelets and 
lymphocytes as compared to controls.  
 
When considering the availability of blood samples for research and the current state of art in 
proteomics, it may seem surprising that there are only few published studies that have mined 
biomarkers in plasma and sera of AD patients (Alafuzoff et al. 1986, Ai et al. 1989, Ueno et 
al. 2000, Zhang et al. 2004). However, in blood, the most abundant proteins i.e. albumin and 
immunoglobulins are considered to obliterate the less abundant ones. In fact, the dynamic 
range of plasma protein concentrations may comprise ten orders of magnitude. The disease-
specific biomarkers are suspected to be seen in concentrations of the less abundant proteins 
i.e. in the "deep proteome" consisting of only 1% of proteins in the whole blood proteome 
(Righetti et al. 2005). In order to study the less abundant proteins, several prefractionation 
methods and steps are required. Moreover, the removal of high abundance proteins may 
concomitantly remove associated proteins. The problem of the "deeper proteome" is not 
limited to blood since biomarker research and expression proteomics using other body fluids 
also suffer from the wide range of protein concentrations. 
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2.3.2. Post-translational modifications 
 
Despite the recent developments in the detection of modified proteins, these techniques have 
rarely been used to study proteomes of AD patients. In 2-DE studies, modifications are still 
mostly reflected on the basis of isoform distribution. Oxidation, phosphorylation and 
glycosylation are a few examples of modifications that have been studied in AD.  
 
2.3.2.1. Oxidation 
 
Carbonylation as a sign of oxidation is currently the most common modification of proteins 
which has been studied in AD using 2-DE based proteomics. It is based on ROS oxidising 
amino acid residue side-chains into ketone or aldehyde derivatives called protein-bound 
carbonyls (Levine et al. 1990, Berlett and Stadtman 1997, Dalle-Donne et al. 2003b). 
Carbonyl groups can also be introduced into proteins by lipid peroxidation or glycation. 
Carbonylated proteins can be derivatised, and studied by two-dimensional (2-D) oxyblotting 
based on separation of proteins by 2-DE followed by immunodetection of the derivatised 
carbonylated proteins (Shacter et al. 1994, Nakamura and Goto 1996). Several carbonylated 
proteins have recently been characterised by 2-D oxyblotting in AD plasma and brain 
(Aksenov et al. 2001, Castegna et al. 2002a, Castegna et al. 2002b, Choi et al. 2002, Choi et 
al. 2004, Choi et al. 2005, Sultana et al. 2005) (Table 1).  
 
2.3.2.2. Phosphorylation and glycosylation 
 
Phosphorylation is the most widely studied modification related to AD. Therefore, it is 
surprising that no large-scale clinical 2-DE studies on phosphoproteomes of AD patients have 
been conducted, though there are 2-D immunoblotting studies on tau phosphorylation 
(Ksiezak-Reding et al. 1990, Sergeant et al. 1997, Tolnay et al. 2002). Also, increased 
phosphorylation of elongation factor 2 has been demonstrated in AD brain by the 2-D 
approach (Johnson et al.1992). 
 
 
 Table 1. Oxidised proteins and their levels in AD patients as compared to controls as revealed by 2-DE and 2-D oxyblotting. 
No. of patients 
Control  AD
Name of protein Tissue Deregulated 
levels in AD 
Deregulated 
oxidation in AD 
Participates in References 
6     6 Beta actin SMT NK increase cytoskeletal component Aksenov et al. 2001 
6 
5 
7 
6 
5 
7 
Creatine kinase BB SMT 
IPL 
H 
 
 
decrease 
increase 
increase 
stress response Aksenov et al. 2001 
Castegna et al. 2002a 
Schonberger et al. 2001 
5 
6 
5 
6 
Glutamine synthase IPL 
CC 
 
decrease 
(total) 
increase glutamate-glutamine cycle,
astrocytic 
 Castegna et al. 2002a 
Robinson 2000 
5 
6 
7 
5 
6 
7 
DRP-2  IPL
H 
CG 
 
decrease 
decrease 
increase 
increase 
neuronal protein, synaptic 
transmission 
Castegna et al. 2002b 
Sultana et al. 2005 
Schonberger et al. 2001 
5 
11 
5 
10 
HSC 71 IPL 
TP 
 
decrease 
increase stress response Castegna et al. 2002b 
Yoo et al. 2001  
5 
6 
7 
7 
5 
6 
7 
7 
Alpha enolase 
 
IPL 
H 
H 
CG 
 
increase 
increase 
increase 
increase 
increase 
glycolysis Castegna et al. 2002b 
Sultana et al. 2005 
Schonberger et al. 2001 
Schonberger et al. 2001 
5 
5 
5 
5 
UCH-L1  IPL
FC 
 
decrease 
increase 
increase 
proteolytic degradation of 
proteins 
Castegna et al. 2002a 
Choi et al. 2004 
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 6 
7 
6 
7 
H 
EC 
increase 
decrease 
increase Sultana et al. 2005 
Schonberger et al. 2001 
5 
 
7 
5 
 
7 
SOD 1 FC 
 
H 
increase 
(total) 
increase 
increase stress response, antioxidant 
enzyme 
Choi et al. 2005 
 
Schonberger et al. 2001 
9 
7 
9 
7 
Alpha-1-antitrypsin 
precursor 
plasma 
CSF 
 
increase 
increase acute phase protein Choi et al. 2002 
Puchades et al. 2003 
9  9 Fibrinogen-γ-chain plasma NK increase polymerises into fibrin and 
involved in platelet 
aggregation 
Choi et al. 2002 
6      6 Pin-1 H decrease increase cell cycle, chaperone Sultana et al. 2005 
6 6 PGM1 H decrease increase glycolysis Sultana et al. 2005 
6       6 Gamma-SNAP H increase increase secretory vesicular
transport, neurotransmittor 
release 
Sultana et al. 2005 
6 6 TPI H increase increase glycolysis Sultana et al. 2005 
6 6 Carbonic anhydrase II H increase increase acid-base balance Sultana et al. 2005 
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DRP-2, dihydropyriminidase-related protein; Gamma-SNAP, gamma synaptosomal protein like soluble A-ethylmaleimide-sensitive factor 
attachment proteins; HSC 71, heat shock cognate 71; PGM1, Phosphoglycerate mutase; Pin-1, peptidyl prolyl cis-trans isomerase; SOD1, TPI, 
triosephosphate isomerase; UCH-L1, Ubiquitin carboxyl-terminal hydrolase isozyme L1 
CC, cerebral cortex; CG, cingulate gyrus; FC, frontal cortex; EC, entorhinal cortex; H, hippocampus; IPL, interior parietal lobe; SMT, superior 
and middle temporal gyri,;NK, not known 
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There are few clinical 2-DE-based studies into glycosylation. An interesting approach was 
applied by Yu et al. 2003 who examined native and oxidised glycoproteins in AD plasma. 
They first isolated glycoproteins by affinity chromatography with heparin-agarose and 
Concavalin A. Thereafter, 2-D oxyblotting and evaluation of the levels of glycoproteins were 
carried out. They found increased amounts of glycosylated transferrin, hemopexin and α-1-
antitrypsin (α-1-AT) in AD patients as compared to controls. Both glycosylated hemopexin 
and transferrin also exhibited increased levels of oxidation in AD. Moreover, in 2003, 
Desrosier et al. reported using 2-immunoblotting that the levels of serum melanotransferrin or 
affinity purified glycosylated isoforms are not suitable diagnostic markers for AD. Another 
type of approach was applied by Kanninen et al. 2004 using multiplexed proteomics. They 
separated the most abundant cytosolic brain proteins by 2-DE and stained glycoproteins with 
Pro-Q Emerald 300, and measured the levels of proteins after Sypro Ruby staining. About 50 
glycoproteins and 150 proteins were detected on 2-D gels, suggesting that more than 30% of 
all proteins may be regulated by glycosylation. Altered levels of glycosylation were found for 
collapsin response mediator protein 2 and an unidentified protein. GFAP tended to be more 
glycosylated in AD, and heat shock protein 71 and creatine kinase BB were identified as 
glycoproteins.  
 
2.4. MULTIPLE USES OF CLINICAL PROTEOMICS 
 
Clinical proteomics aims at both individual patient monitoring and at achieving a better 
understanding of disease processes manifested by typical symptoms and biochemical 
alterations. From the diagnostic point of view, the aims are to find early disease stage 
markers, to be able to evaluate the risk of developing a disease, to follow-up the progression 
of a disease, to predict the prognosis of a disease, and to be able to monitor the effects of 
treatment. From the point of view of drug discovery and pharmacology, proteomics may 
assist in faster development and validation of molecules for medical intervention in disease 
processes.  
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3. AIMS OF THE STUDY 
 
Proteomics is attracting an increasing amount of interest in its applications to better 
understand disease processes, to search for new biomarkers, and to accelerate drug 
development. Accordingly, the initial aim of the present studies was to establish 2-DE and 2-
D immunoblotting methods for studying both the levels and post-translational modification of 
individual proteins. In addition, our working hypothesis was that proteomic analysis would 
reveal new protein changes that are related to the pathogenesis of AD, and could be potential 
biomarkers for the diagnosis of AD. 
 
The specific aims of the present study were: 
 
1) To develop a multiplexed proteomics approach for simultaneous examination of the 
levels and oxidation of multiple proteins in AD. (I)  
 
2) To apply the multiplexed proteomics approach for quantification of oxidatively 
modified proteins in brain and CSF of AD patients. (I, II, IV) 
 
3) To develop other approaches to study PTMs such as glycosylation and 
phosphorylation in AD; as an example we chose GFAP. (III) 
 
4) To analyse the relationship of protein changes between clinical and neuropathological 
data. (II-III) 
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4. MATERIALS AND METHODS 
 
4.1. STUDY SUBJECTS 
4.1.1. Brain samples  
 
The post-mortem tissue was obtained from the Kuopio Brain Bank, Kuopio University 
Hospital. The permission for sampling of brain tissue was granted by the Finnish National 
Board of Medical Legal Affairs, and the study was approved by the Ethical Committees of 
the Kuopio University Hospital and University of Kuopio. All patients were 
institutionalised and evaluated clinically by a neurologist prior to death. The clinical 
diagnosis of probable AD was based on the consensus criteria of NINCDS-ADRDA 
(McKhann et al. 1984) and the DSM-III-R criteria (American Psychiatric Association 
1987). For the assessment of AD pathology, subjects were classified into neuropathological 
groups as recommended by the guidelines established by Braak & Braak (1991a, 1991b) 
and by CERAD. AD patients were selected based on the severity of dementia (Braak stages 
V-VI) and the absence of histological changes other than those related to AD. Control 
cases were age-matched and classified as normals according to CERAD and represented 
Braak and Braak stages I-IV (Mirra et al. 1991). Further, the retrospective evaluation of 
medical records of controls did not indicate any signs of cognitive impairment or other 
neurological deficits. APO E genotype was characterised as previously described (Hixson 
et al. 1990, Tsukamoto et al. 1993). Patient demographics are presented in Table 2. 
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Table 2. Patient demographics 
Study Diagnosis n Women/
Men  
(n) 
Apo E 
ε4+ 
(n) 
Age 
(years) 
Duration 
of CI 
(years) 
PMD 
(h) 
Brain 
weight 
(g) 
Control 9 2/7 1 82±2 - 13±3 1322±7I , II 
AD 10 9/1 7 83±2 12±4 5±1 1111±3
Control 12 4/8 2 80±3 - 20±5 1320±5III 
AD 12 11/1 9 83±2 11±1 5±1 1113±4
AD, Alzheimer's disease; Apo E ε4+, number of subjects having one or two copies of 
apolipoprotein E ε4 allele;  Duration of CI, duration of clinical impairment; PMD, 
post-mortem delay 
 
4.1.2. Cerebrospinal fluid samples  
 
CSF samples were collected as a part of the ongoing biomarker project, and obtained from 
eleven AD patients and from nine neurological controls showing no cognitive decline (Table 
3). Informed consent of participation in the study was obtained from all subjects and 
caregivers of demented patients. The study was approved by the local ethics committees of 
University of Kuopio and Kuopio University Hospital. The diagnosis of probable AD was 
established according to NINCDS-ADRDA criteria (McKhann et al. 1984). Mini Mental State 
Estimation (MMSE) is a commonly used short test battery for screening of cognitive status 
and it was used to assess the severity of AD (Folstein et al. 1975). Lumbar puncture was 
performed using a standardised protocol followed by immediate freezing and storage of CSF 
samples at -70oC until use. 
 
Table 3. Patient demographics. 
Study 
 
Diagnosis n Women 
/Men (n) 
Apo E  
ε 4+ (n) 
Age 
(years) 
Duration of 
CI (years) 
MMSE 
(score) 
Control 9 3/6 4 65±3 - 24±1 IV 
AD,MCI/AD 11 8/3 8 74±3 2±0 21±1 
AD, Alzheimer's disease; Apo E ε4+, number of subjects having one or two copies of 
apolipoprotein E ε4 allele;  Duration of CI, duration of clinical impairment; MMSE, scores 
obtained in Mini Mental State Examination 
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4.2. NEUROPATHOLOGY AND IMMUNOHISTOCHEMISTRY  
 
According to the dissection protocol used in the Kuopio University Hospital, the brains 
were weighed, evaluated for grossly detectable lesions and vessel abnormalities. For 
electrophoreses, tissue samples were obtained from the left hemisphere, frontal cortices 
(Broadman area 9). The fresh brain specimens were stored immediately after dissection at  
-70 oC until use. The right hemisphere was fixed in 10% buffered formalin for at least one 
week and cut in coronal slices of 1 cm thickness. For diagnostic purposes, brain specimens 
were taken from 15 standard cortical and subcortical regions, embedded in paraffin and cut 
into 7µm-thick sections that were stained routinely applying haematoxylin and eosin and 
modified Bielschowsky silver impregnation. In brain proteome studies II and III, data of 
immunohistochemistry were taken into consideration in order to further assess the 
quantitative pathology in relation to the proteomics data. The quantification of Aβ 
aggregates, PHF-tau, GFAP labelled RAs and HLA DR labelled AM was performed as 
previously described (Kraszpulski et al. 1998, Alafuzoff et al. 1999, Overmyer et al. 
1999b, Overmyer et al. 1999a) 
 
4.3. SAMPLE PREPARATION FOR ELECTROPHORESIS  
 
In studies I−III, brain samples were homogenised in 50mM Tris-HCl, pH 7.4, 1mM EDTA 
and protease inhibitor cocktail Complete (Roche Molecular Systems, Almeda, CA, USA). 
Soluble fractions containing equal amounts of Tris-HCl soluble proteins were separated by 
centrifugation at 13 800xg at 4oC for 15 minutes prior to precipitation of proteins with 10% 
TCA on ice for 30 minutes. Precipitates were then washed three times with ethanol-ethyl 
acetate (1:1, V/V). In study IV, individual CSF samples containing equal amounts of protein 
were precipitated with ice cold acetone (1:2, V/V) and incubated overnight at -20 oC followed 
by a centrifugation at 5000 x g at 4oC for 15 minutes. After precipitation, proteins were 
dissolved in the appropriate sample buffer for either one-dimensional gel electrophoresis (1-
DE) or 2-DE experiments. 
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4.4. TWO-DIMENSIONAL GEL ELECTROPHORESIS 
 
Precipitated proteins were dissolved in sample buffer containing 7 M urea, 2 M thiourea, 4% 
CHAPS, 20 mM dithiothreitol (DTT), and a trace of bromophenol blue (BPB). Additionally, 
in studies I and II, 0.5% of IPG buffer was added to the sample buffer prior to IEF. In studies 
III and IV, the amount of IPG buffer was increased to 1% since it seemed to improve the 
resolution of proteins on 2-D images. Isoelectric focusing was performed using IPG strips 
(Amersham Biosciences) and an IPGphor focusing unit (Amersham Biosciences, Uppsala, 
Sweden). A more detailed description of the IEF conditions is presented in Table 4. 
 
Table 4. Summary of IEF conditions in each study. 
Study Tissue pI range Amount of IPG 
buffer (%) 
 
IPG strip 
length 
(cm) 
Duration of 
IEF 
(Vhr) 
I, II Brain 3-10 NL 0.5 7 11 500 
III Brain 4-7 1 7 11 500 
IV CSF 3-10 NL 1 18 32 500 
IEF, Isoelectric focusing; IPG, immobilised pH gradient; pI, isoelectric point 
 
Before the 2nd dimension SDS-PAGE separation, IPG strips were removed from the 
IPGphor apparatus, reduced and alkylated with a solution containing 50mM Tris-HCl (pH 
8.8), 6M urea, 30% (v/v) glycerol, 2% SDS, and a trace of BPB. Additionally, the 
reduction step contained 1% DTT, and the alkylation step 3.5% iodoacetamide (IAA). In 
brain proteome studies I-III, proteins were separated according to their Mr on 10% SDS-
PAGE with Mini Protean II (Bio-Rad, Hercules, CA, USA). In the CSF study IV, proteins 
were separated by 12.5% SDS-PAGE with Protean II (Bio-Rad, Hercule, CA, USA). 
 
4.5. ONE-DIMENSIONAL GEL ELECTROPHORESIS  
 
Precipitates of brain protein extracts were first dissolved in Laemmli sample buffer 
(Laemmli 1970) and separated according to their Mr using 10% SDS-PAGE with Mini 
Protean II (Bio-Rad, Hercules, CA, USA) (II-III). 
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4.6. IMMUNOBLOTTING  
 
After either 1-DE or 2-DE, proteins were electrotransferred to Hybond-P (Amersham 
Biosciences) PVDF membranes in Towbin transfer buffer by using Mini TransBlot (Bio-Rad) 
(I-III) or Protean II Transfer apparatus (Bio-Rad) (IV). Membranes were then blocked with 
5% skimmed milk in PBS-Tween, and incubated with the primary antibody overnight at 2-8 
oC. Membranes were washed with PBS-Tween and incubated with the secondary Cy5-
labelled antibody for two hours at room temperature followed by washing with PBS-Tween. 
All secondary antibodies were purchased from Jackson Immunoresearch Laboratories, West 
Grove, PA, USA. Fluorescence signals were detected by fluoroimager Storm 860 (Amersham 
Biosciences, Uppsala, Sweden) at the wavelength of 635nm. The primary antibodies used for 
immunoblottings are listed in Table 5. 
 
Table 5. Primary antibodies for immunoblotting. 
Study Name  Application Dilution Source 
I-IV Rabbit anti-DNP 2-D 1:1000 Dako, Glostrup, 
Denmark 
II,III Rabbit anti-cow GFAP 1-D 1:3000 Dako 
III Rabbit anti-cow GFAP 2-D 1:1500 Dako 
II Sheep anti-pig heart MDH1 1-D 1:1500 Rockland, Gilbertsville, 
PA, USA 
II Rabbit anti-bovine liver GDH 1-D 1:1500 Rockland 
Application, indication of 1-D or 2-D immunoblotting; DNP, dinitrophenyl; GFAP, glial 
fibrillary acidic protein; MDH1, cytosolic malate dehydrogenase, GDH, glutamate 
dehydrogenase  
4.7. TWO-DIMENSIONAL MULTIPLEXED OXYBLOTTING  
 
In order to detect carbonylated brain proteins, tissue extracts were derivatised with 2mM 2,4-
dinitrophenylhydrazine (DNPH) (Sigma, St. Louis, MO, USA) in 2N HCl prior to TCA 
precipitation during sample preparation (I-III) (Figure 6). In study IV, the derivatisation of 
CSF proteins took place after IEF, IPG strips were incubated in 10 mM DNPH in 2N HCl and 
equilibrated according to the "in-strip derivatization" method described by Conrad et al. 2001.  
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Otherwise, brain and CSF proteins were separated by 2-DE and immunoblotted essentially as 
described in sections 4.4 and 4.6. However, in order to detect protein levels, PVDF 
membranes were first stained with Sypro Ruby fluorescent protein stain according to the 
manufacturer's instructions (Bio-Rad), and scanned at 450nm by fluoroimager Storm 860 
(Amersham Biosciences). Thereafter, membranes were incubated with anti-dinitrophenyl 
(DNP) primary antibody followed by visualization of protein-bound carbonyls with 
fluorescent Cy5-labelled secondary antibody.  
 
  
Protein-
bound 
carbonyl 
2,4-dinitrophenylhydrazine 
(DNPH) 
2,4-dintrophenylhydrazone 
(DNP) 
 
 
Figure 6. Demonstration of the derivatization of protein-bound carbonyls with DNPH, which 
becomes covalently attached to the peptide backbone. The resulting DNP-group is detected 
with an antibody as a marker of oxidative modification of the protein. 
 
4.8. DEGLYCOSYLATION AND DEPHOSPHORYLATION OF GFAP  
 
In study III, brain proteins were deglycosylated and dephosphorylated prior to sample 
preparation. Deglycosylations of N-linked oligosaccharides and complex O-linked 
carbohydrates having the Gal-β(1-3)-GalNAc core structure were performed using a 
commercial enzymatic protein deglycosylation kit E-DEGLY (Sigma, Saint Louis, MI, USA) 
according to the manufacturer’s instructions under denaturing conditions. Lambda Protein 
Phosphatase system (New England Biolabs Inc, Beverly, MA, USA) was used to remove 
phosphorylations attached to serine, threonine and tyrosine residues according to the 
manufacturer’s instructions. Protein samples were then separated by 2-D immunoblotting. The 
existence of glycosylations and phosphorylations was determined by comparing treated and 
untreated 2-DE patterns of GFAP. 
 
 C=O + H2N-NH                         NO2
NO2 
H+
 =C=N-NH                         NO2 + H2O
NO2
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4.9. PROTEIN IDENTIFICATION  
 
After 2-DE, proteins were stained with Sypro Ruby gel stain according to the manufacturer’s 
instructions (Bio-Rad, Hercules, CA, USA). Proteins of interest were manually cut out on a 
UV-table, reduced and alkylated, in-gel digested with trypsin and desalted as previously 
described (Rosenfeld et al. 1992, Shevchenko et al. 1996, Nyman et al. 2000). The detailed 
protocols for in-gel digestion and desalting can be found in the web-pages, 
http://www3.btk.utu.fi: 8080/Genomics/ Proteomics/ Protocols. The resulting peptides were 
analysed by MALDI-TOF MS or by nanoscale liquid chromatography tandem mass 
spectrometry (LC-MS/MS). Database searches were performed using the Mascot Search 
engine (http://www.matrixscience. com) or with BioAnalyst 1.0 software and database 
searches with PepSea Server version 2.2.1.7. 
 
Alternatively, proteins were in-gel digested as described by Kanninen et al. 2004, and the 
resulting peptides were analysed using high performance liquid chromatography electrospray 
ionization tandem mass spectrometry (HPLC-ESI-MS/MS) (III). The proteins were identified 
with peptide molecular weight and MS/MS data using Sequest search program (Thermoquest, 
San Jose, CA).   
 
4.10. IMAGE ANALYSIS 
4.10.1. Two-dimensional images 
 
Fluorescence intensities of detected proteins on membranes were analysed by using 
ImageMaster 2D Elite software (Amersham Biosciences). One of the membranes of a control 
sample was chosen to serve as the reference gel during the image analysis. Protein spots were 
detected and matched among 2-D membranes in order to compare and correlate differences 
between AD patients and age-matched controls. Averaging was not performed during image 
analysis. This means that the membranes were not grouped according to the diagnosis during 
the image analysis, but the values of light intensities of individual spots were taken separately 
from each membrane to the statistical analysis. In studies I-II, oxidised brain proteins 
detected by anti-DNP immunoblotting, and proteins stained by Sypro Ruby fluorescent stain, 
were analyzed separately. In studies I-II, both the levels and oxidation of brain proteins were 
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given as normalised values. Also in study IV, the levels of CSF proteins were given as 
normalised values. For the comparison of the levels of proteins, the normalised value was 
justified since the total amount of protein loaded to each gel was the same. However, the 
carbonylation of CSF proteins were given as light intensity values after realising that the 
equal amount of total protein cannot be expected to exhibit the same degree of modification in 
individuals. We also tested the analysis of carbonylation of CSF proteins (IV) using 
normalised values and carbonylation of brain proteins (II) using intensity values. Fortunately 
and unexpectedly, these differences in analyses did not influence the results. The levels of 
GFAP were analysed as intensity values, and not as normalised values, since it was assumed 
that individuals did not have equal amounts of the immunodetected protein (III). Measures of 
light intensities were transferred to SPSS for statistical analysis. 
 
4.10.2. One-dimensional images 
 
In brain proteome studies II and III, the light intensities of immunoblotted proteins including 
cytosolic malate dehydrogenase (MDH1), glutamate dehydrogenase (GDH), and GFAP were 
measured by using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). 
Values of light intensities were transferred to SPSS for statistical analysis. 
 
4.11. STATISTICAL ANALYSIS 
 
Mann-Whitney’s U test (SPSS Inc., Chicago, IL, USA) was used to compare light intensities 
of detected proteins. The degree of oxidation was calculated as the ratio of protein-bound 
carbonyls to the amount of protein. Furthermore, in brain proteome studies II and III, the 
relationships between post-mortem delay (PMD), duration of the clinical impairment, age at 
onset, age at death, brain pathology and protein changes were calculated by Pearson’s 
correlation test (SPSS Inc.). In study III, a curve diagram was created from the average values 
of the amounts of GFAP isoforms, the area under curve (AUC) was calculated, and the curves 
were further fitted into a log normal mathematical equation (SigmaPlot). 
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5. RESULTS 
 
5.1. IDENTIFICATION OF PROTEINS  
 
The multiplexed quantitative 2-D oxyblotting approach for the simultaneous measurement of 
the amounts and carbonylation of proteins on a single membrane was developed in study I. 
Thereafter, in study II, brain proteins exhibiting oxidative changes in AD patients as 
compared to age-matched controls were further characterised. In study IV, the multiplexed 2-
D oxyblotting method was adapted to study oxidatively modified CSF proteins in AD patients 
as compared to controls. In study III, the levels of GFAP isoforms, and their phosphorylation, 
glycosylation, and oxidation were studied in AD brain. As a consequence of the results 
obtained by 2-D immunoblottings, a total of 14 brain and 30 CSF proteins of interest were 
identified by MS and database searches. These proteins are presented in Figures 7 and 8 and 
Tables 6 and 7. The numbering in the figures and tables is followed hence when presenting 
the results. 
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Figure 7. 2-DE image of the most abundant human frontal cortex proteins highlighting 
proteins selected for identification. Proteins were separated first according to their pI using 18 
cm 3-10 NL IPG gel. In the second dimension, proteins were separated according to their Mr 
using 12.5% SDS-PAGE gel. Proteins were visualized with Sypro Ruby fluorescent stain and 
cut out manually for in-gel digestion and identification.  
 
 
 
Table 6. Identified human brain proteins 
 
# 
 
Protein 
Acc. No. No. of 
peptides 
Seq. cov. 
(%) 
Study 
1 Carbonic Anhydrase I P00915 5 25 II 
2 Malate dehydrogenase 1 a P40925 5 19 II 
3 Malate dehydrogenase 1 b P40925 20 49 II 
4 Aconitase, mitochondrial Q99798 9 14 II 
5 Glutamate dehydrogenase P00367 10 22 II 
6 14-3-3 protein zeta/delta P29312 14 55 II 
7 Aldolase C P09972 10 35 II 
8 Aldolase A P04075 7 17 II 
9 ATP synthase beta chain, mitochondrial P06576 10 24 II 
10 Gamma-enolase P09104 2 6 III 
11 Creatine kinase, B chain P12277 5 18 III 
12 Beta-actin P02570 1 5 III 
13 Gamma-actin P02571 6 19 III 
14 Glial fibrillary acidic protein P14136 3 7 III 
#, number of protein; Acc. No, identification of proteins is indicated by SWISS-PROT 
accession numbers; No. of peptides, number of peptides matched; Seq. cov., sequence 
coverage of matched peptides. 
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Figure 8. 2-DE image of the most abundant human CSF proteins. A total of 30 proteins were 
selected to be identified in study IV. Proteins were separated using 18 cm long 3-10 NL IPG 
gel and 12.5% SDS-PAGE gel. Proteins were visualized with Sypro Ruby fluorescent stain 
and cut out manually for in-gel digestion and identification.  
 
 
Table 7. Identified proteins in human cerebrospinal fluid (study IV). 
# Name Acc. No. Score 
1 Vitamin D binding protein 21730549 46 
2 Vitamin D binding protein 22219267 67 
3 Vitamin D binding protein 22219267 72 
4 Vitamin D binding protein 72105 54 
5 Alpha-1-antitrypsin precursor 1942629 65 
6 Alpha-1-antitrypsin precursor 7245932 54 
7 Alpha-1-antitrypsin polymer 7245932 80 
8 Alpha-1-antitrypsin precursor P01009 94 
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9 Alpha-1-antitrypsin precursor P01009 67 
10 Alpha-1-antitrypsin precursor P01009 91 
11 Apolipoprotein E3 178853 85 
12 Apolipoprotein E3 1942471 84 
13 Apolipoprotein E 338305 75 
14 Apolipoprotein E 178853 63 
15 Apolipoprotein J 338305 79 
16 Unidentified -  
17 Lambda chain precursor 33395 54 
18 Unidentified - - 
19 Beta-trace (N-terminal peptide from human CSF) 410564 48 
20 Beta-trace (N-terminal peptide from human CSF)  18028972 77 
21 Beta-trace (N-terminal peptide from human CSF) 18028972 125 
22 Proapolipoprotein 178775 94 
23 Proapolipoprotein 178775 125 
24 Proapolipoprotein 178775 106 
25 Beta-trace 18028972 53 
26 Cu/Zn-superoxide dismutase 1237406 62 
27 Unidentified - - 
28 Transthyretin 339685 68 
29 Transthyretin 14719497 80 
30 Transthyretin 999653 80 
#, number of proteins; Acc.No., identification of proteins indicated as NCBI or SWISS-PROT 
accession numbers; Score, probability based mowse score where individual ions scores > 47 
indicate identity or extensive homology (p<0.05). 
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5.2. OXIDATIVELY MODIFIED PROTEINS  
5.2.1. Brain 
 
The 2-D oxyblot application used was developed in study I, in which we detected about 150 
cytosolic proteins and 100 oxidised proteins. In study II, proteins exhibiting significant 
changes in oxidation status in AD brains were identified (Table 8). All oxidised proteins were 
not always quantified since the same spots were sometimes detected in only a few of the 
membranes or did not achieve the sufficient resolution to be analyzed by the image analyses 
software. Proteins exhibiting differences in the levels and oxidation status between AD 
patients and controls are presented in Table 8. Since MDH1 and GDH were characterised as 
less oxidised proteins in AD brains, we also measured the total levels of the proteins by one-
dimensional (1-D) immunoblotting. No difference in the amount of MDH1 was found between 
AD patients and controls. However, the total soluble level of GDH was significantly increased 
by 60% in AD patients.    
 
5.2.2. Cerebrospinal fluid 
 
The oxidation status of proteins did not generally differ significantly between AD patients and 
controls showing no cognitive decline (Figure 9). Only one of the identified proteins, lambda 
chain precursor, was found to exhibit increased oxidation in AD patients. In contrast, the 
levels of proteins tended to be decreased in AD patients as compared to control. Furthermore, 
the oxidation status of proteins generally did not differ significantly between ApoE ε4 carriers 
as compared to non-carriers (Figure 10). Lambda chain precursor was the only identified 
protein exhibiting increased oxidation in ApoE ε4 carriers. Again, the levels of several 
proteins were decreased in ApoE ε4 carriers as compared to non-carriers. Protein levels did 
not generally differ between men and women but the oxidation status of several proteins was 
increased in men (Figure 11). 
 
 
  
 
 
Table 8. Oxidation and levels of brain proteins in AD patients when compared to controls. 
#   Protein Protein-bound carbonyls
(LI) 
Amount of protein 
(LI) 
Degree of oxidation 
   Control
(n=9) 
AD 
(n=10) 
AD vs 
controls 
Control 
(n=9) 
AD 
(n=10) 
AD vs 
controls 
Control 
(n=9) 
AD 
(n=10) 
AD vs 
controls 
1 Carbonic anhydrase 10.96±2.56 26.76±7.13 ↑       165.73±49.2 234.77±49.63 x 0.12±0.03 0.21±0.10 x
2 Malate dehydrogenase 1a 21.54±7.97 8.58±3.12 ↓      142.16±35.54 390.75±72.62 ↑↑ 0.22±0.08 0.03±0.01 ↓↓ 
3 Malate dehydrogenase 1b 32.91±10.70 6.44±1.80 ↓↓      346.73±67.16 579.77±127.61 x 0.16±0.06 0.01±0.00 ↓ 
4 Aconitase         299.24±42.50 156.88±37.08 ↓ 451.10±129.90 254.00±61.74 x 37.11±36.14 2.24±1.59 x
5 Glutamate dehydrogenase 128.81±25.85 88.63±20.42 x      117.37±24.78 227.59±52.84 x 1.61±0.42 1.41±0.91 ↓ 
6 14-3-3 protein zeta/delta 32.38±15.92 3.17±0.90 ↓       636.75±134.63 414.46±77.48 x 0.06±0.03 0.01±0.00 x
7 Aldolase C 127.33±27.44 58.55±11.58 ↓       441.67±81.07 363.24±62.01 x 0.36±0.08 0.46±0.30 x
8 Aldolase A 97.11±27.27 72.95±41.18 ↓       457.89±107.50 179.48±36.01 x 0.23±0.03 0.73±0.56 x
9 ATP synthase beta chain, 
mitochondrial 
588.15±139.74        600.01±82.93 x 795.56±205.85 1544.12±240.01 ↑ 2.59±1.66 0.44±0.06 x 
                                                                               63 
#., number of the protein spot, degree of oxidation, light intensities of protein-bound carbonyls divided by light intensities of the amount of corresponding 
protein spots; LI, light intensity; AD, Alzheimer's disease; vs, versus 
Arrows indicate the levels in AD when compared to controls: x, no difference; ↓ or ↑ (p≤0.05);↓↓ or ↑↑ (p≤0.01). 
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Figure 9. Oxidation and the levels of CSF proteins in AD patients (n=11) as compared to age-
mathced controls (n=9). The degree of oxidation of the spot #18 appeared to be decreased in AD. 
However, the protein spot was detected in only one patient indicating that the protein spot was 
qualitatively more oxidised in AD CSF. 
#, number of the protein spot corresponding to numbering in figure 8 and table 6; PBC, protein-
bound carbonyls; DO, degree of oxidation ratio, protein-bound carbonyls divided by the amount 
of protein; LI, light intensity; 100 x, 1000 x or 10000 x, degree of oxidation multiplied in order 
to fit all the numeric data of one spot onto the same scale; *, p≤0.05; **, p≤0.01. 
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Figure 10. Oxidation and the levels of proteins in Apolipoprotein E ε4 carriers (n=12) as 
compared to non carriers (n=8).  
#, number of the protein spot corresponding to numbering in figure 8 and table 6; PBC, protein-
bound carbonyls; DO, degree of oxidation, ratio, protein-bound carbonyls divided by the amount 
of protein; LI, light intensity; 100x, 1000x or 10000x, light intensities or the degree of oxidation 
multiplied in order to fit all the numeric data of one spot onto the same scale; *, p≤0.05; **, 
p≤0.01. 
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Figure 11. Oxidation and the levels of proteins in women (n=11) as compared to men (n=9).  
 
#, number of the protein spot corresponding to numbering in figure 8 and table 6; PBC, 
protein-bound carbonyls; DO, degree of oxidation, ratio, protein-bound carbonyls divided by 
the amount of protein; LI, light intensity; 100x, 1000x or 10000x, light intensities or the 
degree of oxidation multiplied in order to fit all the numeric data of one spot onto the same 
scale; *, p≤0.05; **, p≤0.01. 
 
 
67 
 
5.3. POST-TRANSLATIONAL MODIFICATION OF GFAP 
 
The total amount of soluble GFAP was increased by 95% in AD brains as compared to the 
age-matched controls (Figure 12A) (III). A total of 46 soluble isoforms of GFAP were 
detected by 2-D immunoblotting (Figure 12B, C). The amounts of only 11 distinct isoforms of 
GFAP were increased in AD as compared to controls. Moreover, nine of them were among 
the higher Mr isoforms 1-11 and 16-27 (Figure 12C), and the quantitative distribution seemed 
to have undergone an acidic shift in AD. In order to further assess the isoelectric shift, a curve 
was created from the average values of light intensities of isoforms 1-11 and 16-27, and the 
AUCs were calculated. The curves were fitted into a four-parametric log normal equation. 
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Spot Diagnosis x0 y0 a b R2 
1-11 Control 4.2665 744851 4131934 0.3073 95.5 
1-11 AD 5.0321 239741 7085167 0.3517 99.6 
16-27 Control 3.2760 883867 5287100 0.4118 99.1 
16-27 AD 4.1503 880828 7463607 0.4523 99.7 
 
 
All curves created from average values and from the equation are presented in Figure 12D and 
indicate a 60% increase in the amount of more acidic isoforms of GFAP in AD for isoform 
trails 1-11 and 16-27. PTM analysis verified that the more acidic isoforms were both 
phosphorylated and N-glycosylated, while the more basic isoforms were O-glycosylated and 
exhibited no quantitative differences between post-mortem AD and control brains.  
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Figure 12. The box in the Sypro Ruby stained 2-DE image indicates the location of the GFAP isoforms (B). An average of five bands and 
46 isoforms were detected by 1-D (A) and 2-D (C) immunoblotting, respectively. Light intensities of individual isoforms were measured 
by 2-D image analysis. Overlapping curves (D) formed by the mean values of light intensities of distinct isoforms (black) and by the four-
parametric equation (grey) revealed an excellent fit with each other. A 60% increase was found for both isoform trails 1-11 and 16-27 in 
AD. The increase was restricted to the more acidic isoforms and the isoform distribution had undergone a qualitative acidic shift in AD 
(lines) when compared to controls (dotted lines). The enzymatic cleavages resulted in changes in the 2-D patterns (E) (oval circles) 
indicating that the more acidic isoforms were N-glycosylated and phosphorylated whereas the more basic isoforms were O-glycosylated. 
The smallest isoforms of GFAP at around 35 kDa exhibited immunoreactivity by 2-D oxyblotting (circle) suggesting oxidative 
modification of these isoforms. GFAP, glial fibrillary acidic protein; PTMs, post-translational modifications; 1-D, one-dimensional;  2-
D, two-dimensional; 2-DE, two-dimensional gel electrophoresis 
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5.4. PROTEIN CHANGES AND NEUROPATHOLOGY 
 
In study II, individual correlations were calculated between brain protein changes and the 
neuropathological data in AD (Tables 12 and 13).  
 
Table 9. Significant correlations between levels of brain proteins, symptoms and 
neuropathological data in AD. 
# Protein Duration of CI Aβ load AM RA PMD 
1 Carbonic anhydrase Ii + +    
5 Glutamate dehydrogenase +     
6 14-3-3 protein zeta/delta   +   
7 Aldolase C    - + 
8 Aldolase A     + 
#, number of the protein spot; Duration of CI, duration of clinical impairment; Aβ, amyloid-
beta; AM, activated microglia; RA, reactive astrocytes; PMD, post-mortem delay, +, 
significant positive relationship;-significant negative relationship 
 
Table 10. Degrees of oxidation of brain proteins correlated significantly with symptoms and 
neuropathological data in AD. 
#. Protein Duration of CI Aβ load AM Braak PMD 
1 Carbonic anhydrase Ii    +  
3 Malate dehydrogenase 1b +     
5 Glutamate dehydrogenase +     
6 14-3-3 protein zeta/delta   +   
8 Aldolase A     + 
#, number of the protein spot; Duration of CI, duration of clinical impairment; Aβ, amyloid-
beta; AM, activated microglia; Braak, Braak and Braak staging; PMD, post-mortem delay +, 
significant positive relationship 
 
In study III, the total amount of soluble GFAP exhibited a positive relationship with AM in 
AD whereas nine distinct isoforms correlated with the extent of astrogliosis in controls. 
Moreover, positive correlations were noted between Aβ load and five mainly basic isoforms 
in controls. Numeric data of the relationships are presented in the original publications. 
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6. DISCUSSION 
 
6.1. SIGNIFICANCE IN RELATION TO ALZHEIMER’S DISEASE  
 
In the present thesis work, proteomic applications were developed for studying both the levels 
and modifications of brain and CSF proteins in AD. In studies I, II, and IV, differences in the 
levels and oxidative modification of brain and CSF proteins were examined between AD 
patients and age-matched controls. In study III, glycosylated, phosphorylated, and oxidised 
GFAP isoforms were studied in post-mortem AD and control frontal cortices. Several 
alterations in the levels and modifications of proteins were found in AD patients as compared 
to the age-matched controls. Moreover, some protein changes were related to the 
neuropathology and duration of clinical impairment. These results may deepen our 
understanding of the pathogenesis of AD.  
 
6.1.1. Oxidatively modified proteins 
 
About 150 cytosolic brain proteins and more than a hundred oxidatively modified proteins 
were detected on 2-D oxyblots using the multiplexed proteomics approach that was developed 
in study I. A total of nine brain proteins were shown to be oxidatively modified and exhibited 
protein changes in AD brains (II). In contrast to the expectations, five of these proteins 
(aconitase, GDH, MDH1a and b, 14-3-3 protein zeta-delta and ATP synthase beta chain) 
tended to exhibit decreased, and only three (CAI, aldolases A and C) increased oxidation 
statuses in AD. In study III, GFAP was identified to be an oxidatively modified protein in AD 
and control brains but there were no differences between the groups. 
 
We found oxidative changes in two mitochondrial enzymes, aconitase and GDH, which are 
intimately involved in the tricarboxylic acid (TCA) cycle (figure 13). Aconitase is considered 
to be the most sensitive enzyme in the TCA cycle to be subjected to H2O2 mediated oxidative 
stress (Tretter and Adam-Vizi 2000) and it is known to be a target of oxidative stress during 
aging (Yan et al. 1997). We found a significant decrease in the amount of aconitase-bound 
carbonyls whereas the amount and degree of oxidation of aconitase exhibited a nonsignificant 
tendency of being lower in AD brains when compared to controls. Since increased oxidation is 
normally related to dysfunction of proteins, these findings are in accordance with the unaltered 
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activity of aconitase in AD frontal cortex as compared to age-matched controls (Bubber et al. 
2005). The second most sensitive enzyme to H2O2 mediated oxidative stress in the TCA cycle 
is the rate-limiting alpha-ketoglutarate dehydrogenase complex (α-KGDHC) (Tretter and 
Adam-Vizi 2000), an enzyme exhibiting reduced activity in AD (Butterworth and Besnard 
1990, Gibson et al. 1998, Gibson et al. 1999, Gibson et al. 2000). As a consequence, the whole 
enzymatic cascade in the TCA cycle becomes sluggish. It can be postulated that GDH may 
compensatorily replace α-KGDHC, and thus catalyse the reaction between α-ketoglutarate (α-
kg) and glutamate (Figure 13) (Erecinska and Nelson 1990, McKenna et al. 2000). It is 
generally assumed that a low level of oxidation of proteins is associated with enhanced 
enzymatic functional status, whereas an increase of oxidation enhances degradation or 
accumulation of proteins (Shringarpure and Davies 2002). Indeed, we found that the degree of 
oxidation was decreased while the total amount of GDH was increased in AD. The latter 
finding was confirmed recently by Burbaeva et al. (2005). The functional consequences of the 
changes in the levels and oxidation of GDH remain to be clarified but they may be 
compensatory, and related to compromised cellular energy metabolism in AD.  
 
The major findings of study II were that the degrees of oxidation of not only GDH but also 
two isoforms of another oxido-reductase, cytosolic MDH1, were significantly decreased in 
AD. This is the first time when oxidatively less modified proteins have been identified in AD 
as compared to previous studies (Table 1). Both of these enzymes are present in neurons and 
astrocytes. GDH is co-localised in cells with aspartate aminotransferase (AAT), which 
participates in the malate-aspartate shuttle with MDHs (Yudkoff et al. 1994, McKenna et al. 
2000, Kimmich et al. 2002) (Figure 13). In addition to GDH, AAT is the only other known 
enzyme catalysing the reaction between α-kg and glutamate (Cooper 1985, McKenna et al. 
2000). The activities of i) GDH have been suggested to be unchanged in temporal cortex of 
AD patients (Butterworth and Besnard 1990), ii) MDH increased in AD frontal cortex (Bubber 
et al. 2005) and iii) AAT increased in CSF of AD patients (Riemenschneider et al. 1997, 
Tapiola et al. 1998). Moreover, enhanced activity of the malate-aspartate shuttle involving 
both MDH1 and AAT has been associated with the late-stages of oxidative stress and to occur 
as a consequence of increased mitochondrial membrane permeability (Atlante et al. 2001). In 
addition, GDH, AAT and MDH are considered to be mostly active during conditions of 
cellular energy deprivation. Thus, these changes may point to the presence of alternative 
metabolic routes in AD since both GDH and MDH may be involved in the production of 
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NADH for the electron transport chain. In addition, decreased oxidation of GDH and MDH1 
may also reflect alterations in neurotransmittor release and thus glutamate-related 
excitotoxicity in AD. Finally, our results indicate the possibility of MDH1 being involved in 
the stress response in AD since this enzyme has been proposed to be identical with alpha-keto 
acid reductase, which is thought to be involved in detoxification of carbonyl species (Friedrich 
et al. 1988, O'Connor et al. 1999, Picklo et al. 2002). 
 
Compromised energy metabolism plays a crucial role in the evolution of AD and it is believed 
to be related to clinical symptoms (Blass et al. 2002). Our results indicated that changes in 
oxidation of MDH1 and GDH were positively associated with the duration of the clinical 
impairment but not with brain pathology in AD. The activity of MDH has been suggested to 
correlate positively with clinical dementia rating scores (CDRs) (Bubber et al. 2005). There 
are no previous data which have correlated the levels or oxidation of GDH with the duration of 
the clinical impairment. However, AD frontal cortex activities of dehydrogenases appeared to 
correlate positively whereas the dehydrogenases with decarboxylase activity negatively with 
CDRs (Bubber et al. 2005).  
  
Abnormalities in the oxidative glycolysis have been reported earlier in AD (Bigl et al. 1996, 
Bigl et al. 1999). Increased oxidations of glycolytic proteins in AD have been found for 
phosphoglycerate mutase and triosephosphate isomerase in hippocampus; as well as for alpha-
enolase in hippocampus and inferior parietal lobe. Our results showed a decrease in the levels 
of protein-bound carbonyls for aldolase A and C (Figure 13). The degree of oxidation of these 
proteins exhibited a non-significant tendency of being higher in AD when compared to 
controls, possibly since also the amounts of these proteins were lower in AD. Our results are 
in accordance with previous studies that have found no changes in the levels or activity of 
aldolases in brains of AD and DS patients (Bigl et al. 1999, Kitzmueller et al. 2001). It is 
possible that aldolases may be modified after death in AD since the degrees of oxidation 
correlated positively with PMD. No such correlations were found in control brains, despite the 
longer PMD. Post-mortem changes may occur in relation to the physiological or to the 
pathological biochemical environment i.e. variations in ante-mortem conditions such as tissue 
pH, may have a variety of unpredictable consequences. 
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Figure 13. The basic neuronal metabolic routes are demonstrated with respect to the results. 
Aldolase is a cytosolic protein involved in oxidative glycolysis. Aconitase catalyses a step in 
the TCA cycle and glutamate dehydrogenase (GDH) a reversible reaction between α-
ketoglutarate (α-kg) and glutamate (Glu). Malate dehydrogenase 1 (MDH1) is a cytosolic 
enzyme involved in the malate-aspartate shuttle, catalysing the reaction between oxaloacetate 
(OAA) and malate. In the malate-aspartate shuttle, malate is taken into the mitochondrion in 
exchange for α-kg and glutamate is taken into the mitochondrion in exchange for aspartate 
(Asp). Aspartate aminotransferase (AAT) functions co-operatively with the malate-aspartate 
shuttle. Both reactions support the release of glutamate as a neurotransmitter and thus also 
influence the glutamate/glutamine (Gln) shuttle between neurons and astrocytes. (Yudkoff et 
al. 1994, Kimmich et al. 2002)  
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Isoforms of CA catalyse the reversible hydration of carbon dioxide, and participate in many 
biological processes including respiration, acid-base balance, and are involved in the 
formation of CSF (Dodgson 1991). The activity of CA has generally been suggested to be 
decreased in AD brain (Meier-Ruge et al. 1984). We found that the levels of CAI-bound 
carbonyls were increased in AD, perhaps reflecting the increase in the total amount of CAI in 
AD brains since the degree of oxidation was not significantly increased. Another isoform, 
CAII, was recently shown to exhibit both increased levels and increased oxidation in 
hippocampus of AD patients (Sultana et al. 2005). Interestingly, the levels of CAI correlated 
positively with the duration of clinical impairment and Aβ-load in AD brains and the degree 
of oxidation exhibited a positive relationship with Braak staging. These correlations may 
reflect pH changes occurring in the AD brain.  
 
Another protein exhibiting a decrease in the carbonyl levels in AD was 14-3-3 protein 
zeta/delta. Human 14-3-3 proteins are highly conserved multifunctional proteins playing an 
important role in various cell-signalling events (Aitken et al. 1992, Yaffe 2002). The amount 
and the degree of oxidation correlated inversely with the extent of activated microglia in AD. 
The only difference between 14-3-3 zeta and delta is that the delta isoforms is phosphorylated. 
A number of cytotoxic agents and cytokines released by activated microglia regulate the 
phosphorylation of 14-3-3 proteins. It is thus possible that the amount and oxidation status of 
14-3-3 protein zeta/delta in someway reflect the extent of AM in AD brain. Although we 
found no significant changes in the amount of any single isoform of zeta/delta, previous 
studies have shown increased levels in several brain regions of some isoforms of 14-3-3 
gamma and epsilon in AD and DS patients (Fountoulakis et al. 1999). 
 
Our findings of decreased or unchanged oxidation of brain proteins do not nullify the 
hypothesis of increased oxidative stress in AD. One reason for decreases in the oxidation 
statuses may be that we studied easily soluble/cytosolic proteins, which may inversely 
correlate with unsoluble aggregates of oxidised proteins in AD brain. Some proteins may also 
be functional in a soluble form, and oxidation statuses and levels of proteins may also reflect 
metabolic changes in AD. Moreover, our results represent protein changes occurring during 
severe end-stage AD in contrast to some studies that have examined protein oxidation in 
patients with moderate AD dementia (Sultana et al. 2005). Some studies have indicated that 
oxidative stress diminishes and the levels of some proteins vary during the progression of AD 
(Nunomura et al. 2001, Lee et al. 2005). Therefore, due to the stage of AD studied here, it is 
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not surprising that our results may differ from other published studies. Changes in the protein 
oxidation status and the amount of protein may be strongly dependent on the type of proteome 
under investigation, the stage and the duration of the clinical impairment as well as on the 
brain pathology of the patient.  
 
In study IV, differences were not only observed in AD patients vs. controls but also in women 
vs. men, and in ApoE ε4 carriers vs. non-carriers. The decrease in the levels of CSF proteins 
seemed to be more closely related with the ApoE genotype than with the clinical diagnosis of 
AD. The material was, however, too small to allow us to draw any definite conclusions. 
Moreover, the statistically most significant differences in oxidation statuses of proteins were 
found between men and women. In studies I-III, there was an imbalance between the genders 
i.e. most AD patients were women and most control subjects were men. In addition, most AD 
patients represented ApoE ε4 carriers and most controls were non-carriers. Due to the small 
number of samples, we were not able to analyse the impact of these imbalances on the brain 
proteins. Imbalances in gender and ApoE genotype are usual in AD studies since both are risk 
factors for the disorder. In the future, it will be important to aim at gender- and ApoE-
matching of patients in proteomic studies.  
 
There are no previous 2-D oxyblot studies on oxidatively modified proteins in AD CSF, and 
therefore the changes observed in oxidative modification cannot be directly compared with 
other proteomic studies. We analysed the levels and oxidation of 22 abundant CSF proteins in 
AD and controls. In general, the extent of oxidation did not vary between AD patients and 
controls. Only two proteins exhibited a significantly higher extent of oxidation in AD patients 
as compared to controls. One protein was identified as blood-derived lambda chain precursor 
protein, which is involved in systemic and localised primary immunoglobulin-related 
amyloidosis (Hamidi Asl et al. 1999, Schröder and Linke 1999). However, since lambda chain 
precursor is not a brain-specific protein, its origin in CSF is difficult to establish. It is possible 
that lambda chain precursor infiltrates into CSF directly from blood. Therefore, changes in 
oxidation and levels of lambda chain precursor may also reflect peripheral changes or some 
phenomenon not related to the pathogenetic processes going on in the brain.  
 
CSF is composed mainly of soluble proteins, and our result of the prevalent trend of decreases 
in the levels of proteins was consistent with previous studies (Davidsson et al. 2002, Puchades 
et al. 2003). A decrease in the amount of several brain proteins in CSF maybe due to 
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decreased production or increased aggregation in brain that may occur during the early stages 
of the disease. Our results confirmed the decreases of beta-trace and transthyretin in AD 
although we were not able to confirm the prominent decreases in the levels of 
proapolipoproteins. This is possibly due to differences in the selection of study subjects 
(Davidsson et al. 2002, Puchades et al. 2003). Instead, we detected decreases in the levels of 
proapolipoprotein in ApoE ε4 carriers vs. non-carriers. The amount of Cu/Zn-superoxide 
dismutase (SOD1), a vital antioxidant enzyme, was also decreased in ε4 carriers. 
Proapolipoprotein and SOD1 have been found in association with amyloid deposits in AD 
brain and both proteins are susceptible to oxidative stress (Harr et al. 1996, Kivatinitz et al. 
1997, Choi et al. 2005). The decreases in the levels of proteins generally tended to be more 
pronounced in ApoE ε4 carriers vs. non-carriers than between AD patients and controls. 
Several proteins exhibited also a tendency of being more extensively oxidised in ε4 carriers. 
These results agree with previous studies that have shown enhanced aggregation of proteins 
and increased vulnerability to oxidative stress in ε4 carriers when compared to the other 
phenotypes (Ramassamy et al. 1999, Ramassamy et al. 2001). 
 
We did not study the overall level of increased oxidative stress in our subjects instead we 
examined the level of carbonylation of individual CSF and brain proteins. The reasons and 
functional consequences for the extent of oxidative modification of these proteins remain 
unknown. Oxidation precedes degradation of proteins and is required for elimination of the 
misfolded proteins. Proteins that are active may be more resistant to oxidation and 
carbonylated proteins may be associated with dysfunctional proteins. Further, carbonyl 
formation under oxidative stress is not the primary event but it is believed to occur after other 
protein damaging modifications such as oxidation of methionine (Dalle-Donne et al. 2003a). 
Since carbonylation is thought to attack already inactivated proteins, it cannot be ruled out that 
protein-bound carbonyls may even represent beneficial changes that are necessary for normal 
physiological functions.  
 
In conclusion, we found new potentially important changes in the levels and oxidation of 
proteins in brain and CSF of AD patients. Some of these changes were associated with clinical 
and neuropathological data, indicating that they reflect functionally relevant changes. The 
results need to be replicated in further studies since the material is too small to allow one to 
draw definite conclusions and to exclude other possible confounding factors. The results 
emphasize that protein isoforms may exhibit a distinct, characteristic response to oxidative 
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stress. Therefore, it may be beneficial to examine the oxidation of proteins more profoundly 
i.e. immunoprecipitate the protein of choice prior to 2-D oxyblotting. The effects of other 
post-translational modifications influencing the susceptibility of protein isoforms to oxidation 
are also far from being understood. In the future it will be important to determine at what stage 
of the disease process the changes in the oxidation status of proteins start to occur. 
 
6.1.2. Post-translational modification of GFAP 
 
In study II we observed that GFAP-labelled astrocytes showed a negative correlation with the 
amount and the degree of oxidation of aldolase C in AD whereas the cytosolic fraction of 
GFAP that was measured by 1-D immunoblotting exhibited a positive correlation with the 
degree of oxidation of aldolase C and GDH in control brains. These results attracted our 
attention because it was already well established that GFAP was an excellent candidate for 
2DE analysis due to its several isoforms (Comings 1982c, Greber et al. 1999, Porchet et al. 
2003), and therefore we decided to examine GFAP and its modifications in detail in study III.  
 
Consistent with the previous studies, we detected an overall increase in the amount of GFAP 
in the frontal cortex of AD patients when compared to controls (Arnold et al. 1996, Bigl et al. 
1999, Overmyer et al. 1999a, Ross et al. 2003). However, only eleven out of 46 distinctive 
isoforms exhibited significant increase. Surprisingly, we were able to fit the average values of 
the quantities into a mathematical equation. According to the profile of isoforms created using 
the equation, the significant increase was limited to the acidic isoforms of GFAP. Further 
analyses revealed that the acidic isoforms were both phosphorylated and N-glycosylated 
whereas the basic isoforms seemed to be O-glycosylated. Therefore, the results indicated that 
not only the amount of GFAP was increased in AD but also that the way GFAP became 
modified may have been shifting the quantitative isoelectric distribution towards the 
phosphorylated and N-glycosylated isoforms of GFAP. Our results emphasize the importance 
of analysis of dynamic isoform-specific levels of proteins in pathophysiological conditions. It 
remains to be determined whether quantities of other AD-related protein isoforms obey a 
similar mathematical distribution as detected for GFAP. The methodology used in study III 
can be adopted to permit examination of the isoelectric distribution of other protein isoforms.  
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It is well-established that GFAP is a phosphoprotein (Noetzel 1990) but it was only recently 
proposed that GFAP is a glycoprotein (Kanninen et al. 2004). Our results not only supported 
these findings but also revealed that GFAP is both N-and O-glycosylated. The quantitative 
acidic shift in the isoform pattern of GFAP may reflect a net effect of changes in both 
phosphorylation and N-glycosylation, since hyperphosphorylation of tau has been reported to 
evoke a similar type of acidic shift in the 2-D pattern as we found for GFAP in AD brains 
(Lefebvre et al. 2003). AD-tau is also known to be N-glycosylated, resulting in an enhanced 
phosphorylation of tau (Liu et al. 2002a, Liu et al. 2002b) whereas O-glycosylation has been 
suggested to be protective against tau phosphorylation (Lefebvre et al. 2003). Indeed, GFAP 
may be another phosphorylated and glycosylated protein involved in the pathogenesis of AD. 
It is also tempting to speculate that the suggested imbalance in the activities of phosphatases 
and kinases in AD may not only affect post-translational modification of tau but also other 
proteins such as GFAP.  
 
The total amount of soluble GFAP, a quantitative marker of RAs, correlated with the counts of 
microglia in AD. It is well-known that microglia secrete inflammatory mediators leading 
astrocyte activation (Norenberg 1994). Further, the levels of several isoforms were related to 
the counts of RAs in controls. These findings indicate that the soluble levels of GFAP may 
increase concomitantly with astrocyte activation in normal aging brain. The Aβ-load 
correlated with several O-glycosylated basic isoforms of GFAP in controls, hinting at a 
connection between astrocytes and βA homeostasis (Guénette 2003, Nicoll and Weller 2003). 
No correlations were found between GFAP and tau or Aβ pathology in AD. The lack of 
correlations between GFAP isoforms, RAs and Aβ in AD brains may be due to the fact that 
the expression of GFAP had reached a ceiling effect due to extensive astrocytosis and 
neuropathology. 
 
6.2. CORNERSTONES AND PITFALLS WHEN INTERPRETING DATA 
 
In clinical expression proteomics, misintepretations of data can occur at every step, from the 
clinical information to the results. Although AD proteomes have been scrutinized during the 
last decade, the published studies are currently difficult, even impossible to be compared with 
each other due to insufficient characterisation of the study material, the small number of 
patients involved in studies and the variations in experimental designs. Results may thus be 
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interpreted to be falsely controversial between proteomic studies although they are simply due 
to logical differences in study designs. Biological and methodological variation is a part of 
random and unbiased nature of proteome analysis.  
 
6.2.1. Study material 
 
One of the current focuses in clinical proteomics is concentrated on the characteristics of 
patients since they substantially influence the results. The patients and samples need to be as 
well characterised as possible since the proteomes are dynamic and the number of patients 
recruited into proteomic studies will commonly remain small due to the methodological and 
computational limitations inherent in the technique (i.e. Table 1 and I-IV). In addition to 
individual proteomic heterogeneity, post-mortem studies are influenced by complex ante- and 
post-mortem events (reviewed by Lewis 2002, Hynd et al. 2003). For example, in studies I-
III, most AD patients died from pneumonia with prolonged agonal stage probably 
accompanied by fever, inflammation and hypoxia; while the controls died from sudden cardiac 
death. It cannot be ruled out that these differences in agonal stages may in some way have 
influenced expression and modification of proteins. There are a number of factors that are 
important confounders in the interpretation of the differences in 2-D-maps between healthy 
and disease states. Insufficient reporting of patient demographics such as duration of the 
disease, severity of dementia or the brain area for sampling is common in many proteomics 
studies. This results in difficulties in the comparison of the studies.  
 
In brain proteome studies I-III, we selected AD patients with severe dementia, short PMDs 
and relatively pure AD-neuropathology without additional pathologies such as vascular 
lesions or synuclein pathology. One problem that is common to the most studies is the 
selection of control subjects. The main selection criteria for the controls in the present study 
were age and cognition. The controls were independently living individuals who experienced 
sudden cardiac death at home. This is one reason for the longer PMDs of controls as 
compared to AD patients (3-64 hours vs. 2-12 hours). Moreover, because assessment of 
cognition was based on retrospective evaluation of the medical records, the possibility of mild 
cognitive changes cannot be completely excluded. The availability of completely "healthy" 
elderly individuals wihout age-related diseases is limited. In addition, it is common that 
controls often have AD-related brain changes to some extent even if they are cognitively 
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unimpaired. This was also the case with our studies since some control patients exhibited a 
limited degree of AD-related neuropathology.   
 
Selection and characterization of the tissue and body fluid to be studied is also important in 
proteomics. Different regions in brain have distinct cellular compositions and functions; and 
thus most likely express variations in their proteomes. Morever, progression and duration of 
AD are also relevant issues in the selection of the tissue. AD is a stage- and region-specific 
disease that evolves following a characteristic pattern of symptoms and pathology in the 
brain. Neurodegeneration starts anatomically and histologically from the entorhinal cortex 
and spreads progressively via hippocampus to the cortical areas (Braak and Braak 1991b, 
Reddy and McWeeney 2005). Therefore, the pathogenic process in AD influences the 
proteomes in brain regions in a time-dependent manner. Our AD cases represented the end-
stage of the disease (Braak and Braak stages V-VI), and therefore the findings cannot be 
generalized to reveal the changes occurring in the early phases of the disease. We used the 
frontal cortex tissue from Broadman area 9. Since the cell structures vary in different 
Brodman areas (Carpenter 1976, England and Wakely 1991), our results are best comparable 
with proteomic studies performed using the frontal cortex specimens from AD patients with a 
long-standing disease. Control subjects fell into Braak and Braak stages I-II (except one 
control who had stage IV) and did not have any PHF-tau pathology in their frontal cortices. In 
addition, controls may have had some amyloid deposits in frontal cortices, which are often 
found in individuals without cognitive deficits. All controls were classified as normal (a or b) 
according to the CERAD criteria.  
 
Patients in the study IV about oxidatively modified CSF proteins had a clinical diagnosis of 
probable AD according to the NINCDS-ADRDA criteria (McKhann et al. 1984). They had 
mild dementia and the duration of clinical impairment was relatively short. The 
neuropathologically verified accuracy of clinical diagnosis of AD has been reported to be 
above 90% in our clinic (Kosunen et al. 1996). The control group included age-matched 
cognitively intact subjects who suffered from neurovegetative or psychiatric symptoms, 
tremor and memory problems but did not have a chronic neurodegenerative disease. As 
previously stated, AD-related pathology is common even in cognitively intact subjects, and it 
cannot be excluded solely on clinical basis. Moreover, patients with a clinical diagnosis of 
AD may possess additional concomitant brain pathologies that may interfere when aiming at 
examining disease-specific changes in CSF. These are common limitations in all studies using 
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clinical patient material. 
 
Unlike genetic determinants such as ApoE genotype and gender, clinical AD is far from being 
a "static" state. There are no biological markers for reliable follow-up of the progression of 
AD and pathological changes in biochemical pathways that are dependent on the disease 
stage. Therefore, proteomic patterns may vary in different disease stages, which need to be 
taken into account in the interpretation of the results. Although no straightforward test exists 
for monitoring the progression of AD, it is most likely that patients with a long duration of 
clinical impairment and low MMSE scores are at a different stage of the disorder as compared 
to patients with progressive MCI or early AD with higher scores. In addition, the selection of 
both the control and AD group may influence the results. For example, in the study of 
Puchades et al. 2003, the levels of CSF proteins were measured in non-age-matched "healthy" 
cognitively intact elderly people with MMSE scores at 29-30 and older AD patients. It is 
obvious that the study subject differed from our material in study IV where the levels of CSF 
proteins were measured in age-matched controls who did not show progressive decline (but 
may have had stable cognitive deficit with MMSE scores between 21 and 29), and in 
AD/MCI patients suffering from mild dementia (CSF puncture may have been taken prior to 
the clinical diagnosis of progressive disorder with MMSE scores between 14 and 26).  
 
In all studies I-IV, individual proteomes among controls seemed to be more heterogeneous as 
compared to AD patients. This finding persisted when examining both the levels and 
oxidation of brain and CSF proteins. This is a fact of life since control groups are often 
composed of individuals suffering from a variety of heterogeneous age-related health 
problems. Moreover, oxidation patterns of the proteins may be especially vulnerable to other 
factors such as genotype (i.e. gender, ApoE ε4 allele), lifestyle (i.e. diet, obesity, exercise), 
and drug treatments (i.e. vitamin replacement therapy) (Vincent and Taylor 2005). In 
addition, oxidative stress is always present in chronic-degenerative conditions such as 
autoimmune diseases (i.e. diabetes, rheumatoid arthritis), vascular disorders (i.e. 
cardiovascular diseases), chronic inflammatory disorders (i.e. asthma) and in cancers (Galli et 
al. 2005). It is not known whether peripheral oxidative stress can influence the oxidation level 
of CNS proteins. 
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6.2.2. Experimental design 
 
There are several reasons why we chose 2-DE in combination with MS and/or 
immunoblotting to study differences in AD and control proteomes. Above all, there is 
currently no single powerful technology for studying quantitative differencies in proteomes in 
diseased and healthy states. Though there are new promising gel-free techniques in 
proteomics, 2-DE in combination with MS and/or immunoblotting still remains the most 
established approach in separating and quantifying multiple proteins in complex mixtures 
followed by identification. In addition, the ability of 2-DE techniques being easily adaptable 
to study modifications of proteins served our aims. Indeed, by slightly modifying the 2-DE 
experiments we were able to study oxidation, glycosylation and phosphorylation of proteins. 
 
As is the case with proteomics in general, neither is there a single powerful 2-DE application 
for revealing comprehensive changes in AD-related proteomes. The results obtained in 2-D 
experiments are always influenced by sample preparation protocols, selected IPG strip lengths 
and pH ranges, sizes of second dimension gels, protein stains, image analysis parameters, 
bioinformatics, and success of protein identification. Although IPG-based 2-DE is a 
commonly used protein separation technique in proteomics, it has a several limitations e.g. it 
is poor at revealing i) low-abundance proteins, ii) hydrophobic proteins i.e. membrane 
proteins, iii) acidic and basic proteins, iv) low and high Mr proteins, and v) individual protein 
heterogeneity (reviewed by Fountoulakis 2004). In particular, 2-DE analysis as a whole, is 
laborous and often requires large amount of sample. 
 
Sample preparation influences the types of proteins to be solubilised and analysed in the 
selected tissue type (Görg et al. 2004). The chemicals and incubation times influence protein 
solubilisation and thus the outcome of the proteome in tissues or body fluids. We separated 
proteins soluble in Tris-HCl buffer for the analysis of brain proteins (I-III). Our protocol 
solubilizes mostly cytosolic proteins and other chemicals may have dissolved different 
proteins. We also precipitated brain proteins with TCA and CSF proteins with acetone. 
Precipitation procedures are important and may lead to differences in 2-D proteome patterns 
i.e. incubation times and chemicals influence the yield and type of proteins to be precipitated. 
Therefore, the results can be reliably compared with studies using comparable sample 
preparation protocols. Sample preparation has improved greatly during recent years and there 
are currently a variety of commercially available kits and means to separate different types of 
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proteomes. Sample preparation methods are essential for the reproducibility of 2-D 
experiments.  
 
The results obtained in 2-D experiments are influenced by IPG gel lengths and pH ranges and 
sizes of second dimension gels. The same protein may be detected using i) 7 cm long 3-10 
NL, ii) 11 cm long 4-7 and iii) 18 cm 5.5-6.5 IPG strips that may resolve the same protein into 
i) one, ii) two and iii) six spots, respectively. Indeed, the number of resolved protein spots can 
vary greatly, depending on the resolution attributable to pH gradients and gel lengths. Also 
the size of the second dimension gel influences the resolution i.e. "the bigger the better". We 
used the small 7cm IPG gel format with pH gradients of 4-7 and 3-10 in studies I-III and the 
long 18 cm IPG gel format with pH gradient 3-10 in study IV. It is very probable that more 
changes may be detected in AD proteomes using larger gel formats and/or narrower pH 
gradients. It is common knowledge that interlaboratory qualitative and quantitative 
differences in the results can be traced to gel sizes. The opposite side of this coin is that the 
permutations provide an excellent opportunity to reveal more and more protein changes by 
choosing different gel sizes and pH gradients.  
 
More than hundred proteins were estimated by the naked eye to be present on our 2-D gels. 
However, not all the proteins were reliably matched to the corresponding protein on a 
reference gel in the image analysis due to too high or low abundancy, poor resolution or 
heterogeneity in the individual proteomes. Difficulties in matching and quantification could 
have been partially overcome by using DIGE technology with an internal protein standard. 
Moreover, we used ImageMaster 2D Elite software, which detects and quantifies proteins in 
"two-dimensional space" on 2-D images. In other words, the protein is detected and quantified 
by the occupied area and the intensity of staining. More protein changes may have been 
detected using new generation software packages; in these the detection of proteins occurs in 
"three-dimensional space". This means that proteins are detected by area and the intensity is 
detected as height leading to transformation of spots into digital mountainlike forms. This 
improves spot detection and quantification due to improved resolution and better estimation 
of the spot size, respectively. 
 
Many individual protein isoforms can be observed on 2-D gels. The resolution of these 
isoforms may differ and there may also be isoform-specific changes in the disease. In theory, 
the levels of an isoform of a protein called (Xa) may be increased in AD, whereas another 
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isoform of the same protein (Xb) may not be detected due to poor resolution or low 
abundance; or else this isoform may exhibit unaltered or decreased levels in AD. In other 
words, the quantitative amount of one isoform does not necessarily reveal anything about the 
amount of total protein. Sometimes it is very difficult to determine whether the isoforms 
detected in different studies are comparable. These issues were clearly demonstrated in study 
III. The acidic shift of isoelectric isoform distribution of GFAP in AD became detectable by 
2-D immunoblotting whereas GFAP remained masked by other overlapping proteins in the 
total protein staining. The decrease and increase of some GFAP isoforms in AD as compared 
to controls was already described in one previous study using total protein staining (Tsuji et 
al. 1999). However, it is not possible to determine which isoforms detected here correlate to 
those reported by Tsuji et al. 1999. In addition, in study II, we identified two isoforms of 
MDH1 but only one of them, the more acidic isoform, exhibited significantly increased levels 
in AD as compared to controls. It is the case that different isoforms may express unchanged, 
increased or decreased levels in proteomic studies. However, this does not necessary mean 
that the results obtained in different studies are in conflict with each other, but may rather 
reflect methodological and biological variation. 
 
In the present series of reports, experimental assemblies enabled us to study the differences in 
the levels and modifications of the most abundant brain and CSF proteins. Hereafter, it will be 
important to go "deeper" into the proteome and to study less abundant proteins. For example, 
all the CSF proteins that were studied are present in the mg/l range, whereas even Aβ and tau, 
which are currently the best known biomarker candidates for a diagnostic laboratory test for 
AD, are present in the ng/l range (Reiber and Peter 2001). To go deeper into the CSF 
proteome, would require either the removal of the most abundant proteins i.e. albumin and 
immunoglobulins that account for about 80% of the total protein content in CSF, and/or to 
prefractionate the sample (Righetti et al. 2005). However, it is challenging to study the 
"deeper" CSF proteome using 2-DE since CSF has low protein concentration (about 250 mg/l) 
(Reiber and Peter 2001), and 2-DE currently requires relatively high amounts of protein (up to 
about 1 mg depending on the methodology). Moreover, the volume of CSF taken per lumbar 
puncture is limited (5-10 ml/puncture). In contrast to CSF, brain tissue is rich in proteins and 
the amplitude is smaller to that of body fluids. There are possibilities and ways to study the 
"deeper" brain proteome using 2-DE i.e. by applying prefractionation steps, narrow pH 
gradients, and large gel formats.  
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The general aim in proteomics is to study proteins on a large-scale. However, this is currently 
rarely the reality since whatever technology is used, proteomic analysis is technically 
challenging. Also, our studies represent the early days of proteomics and a small-scale 
approach. Although we started from more than 100 visualised and modified proteins on our 2-
D images, we ended up with only few protein changes of identified proteins. Since the 
beginning of this thesis work, proteomics techniques have improved greatly and the costs of 
this currently expensive methodology keep diminishing. Undoubtedly, if this work were to be 
repeated today, more changes would be observed. Therefore, it is of the outmost importance 
to keep pace with methodological improvements in proteomics. If we understand how the tool 
works and the limitations of the technology, then the only limits are the limits of human 
ingenuity.  
 
6.3. FUTURE ASPECTS IN CLINICAL PROTEOMICS 
 
Individual laboratories have already exerted major efforts in examining AD proteomes in 
order to clarify the pathogenesis of the disease and to screen for new biomarker candidates. 
Similar to the mapping of human genome (human genome organisation, HUGO), the 
international research society became united in order to map human proteomes, and 
established the human proteome organisation (HUPO, www.hupo.org) a few years ago. 
Currently there are several initiatives under HUPO that all aim at improving and standardising 
proteomics techniques as well as exploring human proteomes in health and disease states. 
Human brain proteome project (HBPP, http://www.hbpp.org) is an open international 
scientific initiative under the umbrella of HUPO (Hamacher et al. 2004). One of the main 
focuses in HBPP is AD (Hanash 2004). Considering the current state of art in proteomics, it 
will be interesting to follow future advances in understanding the pathogenesis of AD as well 
as in biomarker and drug discovery.  
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7. SUMMARY AND CONCLUSIONS  
 
The major objectives in the series of studies were i) methodological developments in 
proteome analysis of differentially post-translationally modified proteins, ii) tracing variations 
in brain and CSF proteomes in AD patients as compared to age-matched controls, and iii) 
assessment of relationships between proteomes and neuropathological data. The following 
conclusions related to the pathogenesis and biomarker discovery in AD can be drawn:  
 
1. About 150 proteins and more than 100 oxidised proteins were detected in both AD and 
control brains using a multiplexed proteomics approach utilizing 2-D oxyblotting. The 
tendency towards increased levels of proteins was often associated with concomitant decreases 
in oxidation. The major finding was that two dehydrogenases, MDH1 and GDH, were 
characterized as less carbonylated proteins according to the degree of oxidation in AD. These 
findings may be compensatory and occur in response to compromised metabolism in AD. (I-
II) 
2. Twentytwo oxidatively modified proteins were characterised in CSF of AD patients and 
controls. The levels of identified CSF proteins were generally decreased whereas the degree of 
oxidation tended to be either unchanged or increased in AD as compared to controls. None of 
the brain-derived proteins exhibited significant changes in the extent of oxidative modification 
in AD. (IV) 
3. PTM and isoform profiles of GFAP have previously remained unclear in AD. Fortysix 
isoforms of GFAP were separated and quantified. Acidic isoforms of GFAP exhibited a 60% 
increase in AD as compared to controls. These acidic isoforms were phosphorylated and N-
glycosylated whereas the basic isoforms were O-glycosylated and revealed no quantitative 
differences between the groups. The data suggest that GFAP may be another abnormally 
phosphorylated and glycosylated protein involved in the pathogenesis of AD. (III) 
4. Protein changes were dependent on the stage and clinical impairment in AD. (II-III) 
5. This series of studies emphasizes the importance of studying modifications of proteins in 
neurodegenerative disorders. Extensive characterisation of PTMs of proteins may help to 
clarify new pathological processes in AD, and possibly provide new candidate targets for 
medical intervention. (I-IV) 
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